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1.1 Learning, memory and age-associated memory impairment (AAMI)
The complex process of memory acquisition and recall in the brain has been studied for decades, but 
we are still far from completely understanding it.  With aging, the ability to learn and remember tends to 
decline, in a phenomenon called age-associated memory impairment. Alzheimer’s disease, for which age 
is the biggest risk factor, is characterized by a more severe memory loss and neurodegeneration. Just as 
in humans, aging rodents too show a decline in the ability to learn and remember, and the hippocampus 
plays an important role in the neurobiology of these deficits. The following sections deal with the cellular, 
molecular and behavioral aspects of memory formation and impairment.
1.1.1 The hippocampus in learning and memory and AAMI
The hippocampal formation, a part of the 3-layered archicortex and widely held to be important in memory, 
information consolidation and spatial navigation is present in all mammals. Counterparts of the hippocampus 
are however found in fish, reptiles and birds where they mediate spatial cognition in ways similar to those 
in mammals [1]. Thus the mechanisms involved in hippocampus-dependent spatial learning should have 
evolved relatively early. The neocortical areas, which occupy the largest proportion of the human brain by 
volume evolved later, and are responsible for higher functions such as thought, language and sensorimotor 
functions [2]. 
The prefrontal cortex (PFC), which is greatly expanded in humans and non-human primates controls 
executive functions, personality, and social behavior [3]. The dorsal PFC has extensive connections with 
brain areas involved in [4] cognitive and attention-related processes and has been shown to be involved in 
working memory [5]. Primate studies have shown that the role of the PFC in memory or short term memory 
is largely that of selective attention rather than memory storage [6]. The prefrontal cortex does not exist in 
mice, but the anterior cingulate cortex (ACC)  has been studied extensively in rodent cognition and plays 
an important role in learning and memory. In humans, the ACC is involved in error detection [7] and reward-
based decision making [5] but studies linking it with memory are scarce. In contrast, the ACC has been 
shown to be involved in consolidation and long-term storage of object and location memory [8, 9] as well as 
in contextual fear memory [10] in mice.
The hippocampus has been established as a key player in short-term memory as well as long-term 
memory. The initial basis for investigating its role in memory was the famous study on the ‘Patient H.M.’ 
in whom surgical destruction of the hippocampus led to an inability to form or recall short-term memories 
while older events were well-preserved [11]. In rodents and non-human primates, a series of ablation 
experiments demonstrated its role in spatial learning [12], associative learning and recognition [13] and in 
the consolidation of fear memory [14].
The cellular structure and circuits in the hippocampus make it a particularly favorable area for the 
electrophysiological study of LTP, and innumerable studies have focused on the rodent hippocampus in an 
attempt to elucidate the molecular mechanisms involved in neuronal excitation, LTP and synaptic plasticity 
(reviewed in [15, 16] ). The murine hippocampal formation is also anatomically distinct and can be isolated 
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for molecular studies with relative ease, facilitating precise and reproducible proteome or RNA profiling. 
The seahorse-shaped structure, located in the medial temporal lobe of the human brain and an analogous 
area in the murine brain, shows very similar circuitry in both species. It is composed of the subfields dentate 
gyrus (DG) and cornu ammonis (CA), which is in turn further divided into the CA1, CA2, CA3. All subfields 
consist of several strata, organized depthwise. The hippocampal pyramidal neurons are large, and the 
stratum pyramidale in the CA regions, packed with pyramidal cell bodies is clearly distinguishable by 
microscopy. Similarly, the stratum granulosum of the dentate gyrus contains the cell bodies of the granule 
cells.  The main input to the hippocampus is from the entorhinal cortex, transmitted via the perforant path 
to the dentate gyrus and CA3. The axons of the granule cells of the dentate gyrus — termed mossy 
fibers  — terminate on the pyramidal cells of the CA1, which in turn send their axons to the subiculum and 
entorhinal cortex. Thus, the hippocampus forms an anatomical circuit loop, but doubtless also contains 
other, smaller pathways of information flow. In various species, hippocampal connections to the amygdala 
[17], the septum, basal ganglia, hyptothalamus, ventral tegmental area [18] prefrontal cortex [19]and the 
cerebellum [20] have been demonstrated.
The cortico-hippocampal connections and the perforant path are very well characterized, and play a critical 
role in memory formation [21]. The Schaffer collaterals, the axons of CA3 pyramidal cells have also been 
important to the current understanding of synaptic plasticity. The synapse formed by the CA3 pyramidal 
axons at the CA1 has been used as a model synapse in several studies of LTP and its place in learning and 
memory has been studied extensively [22]. In mice, the dorsal and ventral regions of the hippocampus have 
been shown to exert distinct functions. The dorsal hippocampus is shown to be involved in spatial memory 
[23] while the ventral hippocampus is more closely connected to the amygdala and plays a role in fear and 
stress responses [24]. 
Another important reason for studying the molecular physiology and pathology of the hippocampus is its 
role in Alzheimer’s disease (AD). The hippocampal formation and its connections are affected early and 
extensively in AD. The hippocampus is a focal point of the pattern of plaques, neurofibrillary pathology and 
neuronal loss that characterize AD [25-27]. The gradual loss of memory abilities that constitute the earliest 
clinical signs of AD highlight the link between memory, AD and the hippocampus.
Interestingly, the dentate gyrus of the hippocampus is also one of the few sites where adult neurogenesis 
or the formation of new neurons and their incorporation into circuits in the adult brain has been established 
[28, 29]. These adult-born neurons are now being increasingly shown to contribute to learning and memory 
[30, 31]. The later-evolving cortical areas characterize human behavior, distinguish it from that of other 
mammals and clearly play a role in learning and the formation and storage of memory. However, the 
hippocampus still holds an important place in learning and memory. The earliest pathological signs of 
Alzheimer’s disease, whose initial symptoms consist of memory decline occur in the hippocampus [25].
For the above reasons, the behavioral, and especially the molecular analysis described in this thesis is 
focused largely on the hippocampus.
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1.1.2 Synaptic plasticity and transcription
1.1.2.1 Synaptic plasticity
The concept of synaptic plasticity is the foundation of our understanding of the neuronal mechanisms 
of learning and memory. Synaptic plasticity is the ability of neurons to respond to changes in activity by 
strengthening certain synaptic connections while weakening others [32]. These changes in the neuronal 
connectivity are thought to underlie learning in response to environmental stimuli [15]. 
Synaptic plasticity may be short-term, mediated by an increase in the amount of neurotransmitter available 
at the presynape, or long-term, which is more commonly studied in the context of learning and memory. 
The best known mechanisms of long term synaptic plasticity are long-term potentiation (LTP) and long term 
depression (LTD). LTP is the potentiation or enhancement of postsynaptic response induced by certain 
presynaptic stimulation patterns [33, 34]. LTD is also activity-dependent, but is characterized by a reduction 
in the efficiency of synaptic transmission at the involved synapses [35].
An important characteristic of LTP is its persistence, lasting from several minutes to several months [36]. 
LTP consists of 2 phases, early LTP and late LTP. Early LTP is the facilitation of transmission by activating 
postsynaptic receptors through phosphorylation, and increased presynaptic neurotransmitter release, 
mediated through postsynaptic feedback to the presynapse. The critical event in late LTP is new protein 
synthesis, which enables structural synaptic changes and the formation of new synapses. It has been 
shown using protein synthesis inhibitors that blocking this step prevents the development of long-term 
memory [37].  Experiments using RNA synthesis inhibitors have demonstrated that new RNA transcription 
is also essential for the maintenance of LTP [38, 39]. Late LTP can be further divided into 2 phases — the 
first can be mediated purely by new protein synthesis in the absence of RNA transcription, and the second 
requires both [40]. 
The biochemical signaling cascades in the induction of LTP involve several mediators, among them are the 
extracellular signal-regulated kinase (ERK) family of mitogen-activated protein kinases. 
ERK is persistently activated during LTP and cause a number of downstream events. Another important 
event is the activation of cAMP response element-binding protein (CREB). The activation of this transcription 
factor plays a key role in initiating the RNA transcription necessary for LTP and is crucial to memory formation 
in many different organisms [41]. 
Initial research on protein synthesis in LTP focused on translation occurring centrally and regulated via 
universal mechanisms. Mechanisms such as the synaptic tagging and capture hypothesis [42] were 
developed to describe how overall increases in protein synthesis could lead to the specific activation and 
strengthening of selected synapses.
Subsequently, decades after the discovery that ribosomal particles are seen in dendrites [43], it became 
clear that in neurons, activity-dependent protein synthesis occurs locally after transport of the relevant 
mRNA to the dendrite [44]. This mechanism enables synapses to exert control on protein synthesis, and 
allows for more rapid availability of new proteins at the synapse [45]. There is also evidence to suggest that 
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dendritic protein synthesis is important in memory consolidation; when dendritic targeting of the plasticity-
relevant CaMKII-alpha mRNA was blocked, reduction in LTP was observed along with impairments in 
spatial and associative memory. 
1.1.2.2 Immediate early genes
The first wave of cellular transcriptional response to stimuli is by the activation of a set of genes called 
immediate early genes (IEGs). First described in viruses [46], the IEG response occurs in a variety of cell 
types such as lymphocytes [47], hepatocytes and cardiac cells [48] as well as in neurons [49]. Most IEGs 
are transcription factors like c-Fos, c-Jun and c-Myc, and Egr1 but the list also includes non-transcription-
factor genes such a tissue plasminogen activator (tPA) [50] and Arc [51].
IEGs are known to play an important role in LTP, and are important mediators of learning and memory. The 
role of IEGs in neuronal plasticity was first revealed after the discovery that LTP-inducing NMDA receptor 
stimulation also caused the upregulation of the IEG Zif268 [49]. Zif268 was later shown to be essential for 
late LTP and the maintenence of long-term memory [52]. Increase in expression of other IEGs such as 
c-Fos during acquisition and early phases of consolidation of memory has been also shown to be a part 
of learning behavior in a number of vertebrates [53]. A subset of these IEGs are seen to be induced again 
during reconsolidation of memory [54].
There are also other critical mediators of the neuronal transcriptional response to a learning stimulus. One 
of these is CREB. CRE-dependent gene expression is pivotal to the learning-induced gene expression 
program. In mice the CRE- response is seen in the specific brain areas responsible for the type of learning 
being undertaken. For example, hippocampus-dependent learning such as associative learning or 
contextual conditioning is accompanied by increases in CRE-dependent gene expression in CA1 and CA3 
areas of the hippocampus while the in amygdala-dependent learning paradigms such as auditory-cue fear 
conditioning the increase is specific to the amygdala [55]. Thus a specific neuronal transcriptional response 
is an integral part of learning and memory encoding.  
1.1.3 Brain gene expression changes in aging and Alzheimer’s disease
Large-scale transcriptome studies of the brain have enabled us to begin to understand several aging and 
cognition-related phenotypes. Aging brings about a change in the transcriptional response of the brain. 
In mice, profiling these patterns in various brain regions revealed that the extent to which aging affects 
different brain regions varies widely, with prominent effects in both the cortex and the hippocampus [56]. 
Similar studies in humans show that the in the sixth and seventh decades, there start to be more and 
more changes in gene expression patterns in various cortical regions [57]. In the human frontal cortex, 
aging is accompanied by lowered expression of several genes that play a role in synaptic plasticity in 
the human prefrontal cortex and the increased expression of genes involved in the response to oxidative 
stress, inflammation and lipid metabolism. These changes start after age 40 [58]. 
Another study of the human prefrontal cortex provided evidence that those genes which decrease with aging 
are likely to be of neuronal origin, while those which increase are more likely to be of glial origin [59]. A study 
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comparing age-associated transcriptional changes across and 4 human brain regions in different cohorts 
suggested an overlap between age-related changes and those associated with neurodegenerative disease 
[60]. Further evidence that the transcriptional program that drives aging is a large component of the one that 
drives neurodegenerative diseases comes from a microarray analysis of temporal lobe gene expression in 
AD patients [61], and a systems biology study comparing the gene networks affected in Alzheimer’s disease 
and aging [62]. The former study found a large overlap between the genes differentially expressed in aging 
and Alzheimer’s disease and the latter showed that both processes shared gene expression derangements 
in mitochondrial processes and synaptic plasticity. 
Interestingly, there is evidence that these baseline changes are relatively small in comparison to the 
transcriptional changes that occur during a response to stimulus. The gene expression changes which 
accompany aging in the murine hippocampus have been studied by microarray, with the results that at 
baseline, there are few differences in gene expression pattern between young mice that perform well on 
behavioral tasks and older mice that are impaired. There is however, a large impairment in the upregulation 
of gene transcription in old animals in response to a learning-relevant stimulus. Young mice show a robust 
learning-associated transcriptional response (2229 genes), which is greatly attenuated in aged, learning-
impaired animals (6 genes) [63]. Similarly, in the rat DG gene expression changes are seen with aging 
(around 1000 genes) and the aging-associated changes relate mainly to neurogenesis [64].  This large 
stimulus-induced transcriptional response appears to be a key event in memory formation, because 
treatment with histone deacetylase inhibitors that increase the expression of some of these genes was able 
to reinstate associative memory in the aged mice [63]
1.1.4 MicroRNAs in learning and memory
MicroRNAs are a class of small (22-26 nt) regulatory RNAs that act post-transcriptionally by binding to 
complementary mRNAs. They can directly block mRNA translation to protein or induce mRNA degradation 
by targeting it to a degradation complex called the RNA-induced silencing complex [65]. Since the relatively 
recent discovery of this class of non-coding RNAs [66] they have been studied widely and their role in a host 
of physiological and pathological processes such as embryonic development [67], hereditary disease [68], 
various kinds of cancer [69], and synapse formation in the nervous system [70] has been established. The 
latest version of the microRNA database contains more than 2500 human microRNAs, and the process of 
new microRNA discovery and annotation is still ongoing [71].
After microRNAs started attracting interest as key regulators of translation, there have been several 
investigations into their role in CNS processes. Most of these studies have involved the selection of a single 
microRNA or a handful of microRNAs based on a screening procedure. The neuronal function of these 
microRNAs and their effect on target mRNAs has then been demonstrated by experimental manipulation 
through microRNA mimics or inhibitors in various model systems. 
One of the first genome-scale studies of microRNAs in synaptic plasticity was carried out in the Aplysia 
synapse [72]. The authors showed that miR-124, a highly conserved brain-enriched microRNA regulates 
transcription factor CREB, which is responsible for the gene expression changes underlying the induction 
of long-term potentiation. In mice the expression of CREB was also later shown to be regulated by the 
brain-specific microRNA miR-134. The deacetylase sirtuin1 was shown to be upstream of miR-134 and to 
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regulate the expression of CREB through this microRNA [73]. MiR-34b, another brain-enriched microRNA 
[72] was also shown to target CREB, albeit in acute myeloid leukemia cells [74]. Thus more than one 
microRNA has been demonstrated via overexpression or inhibition to act on the same target. However,  in 
the physiological situation it is not always clear if the microRNAs act alone, in concert with one another, or 
if one or both of them are critical. 
CREB also acts upstream of microRNAs. The transcription of miR-132 is upregulated via CREB in an 
activity-dependent manner in hippocampal neurons in culture [75]. miR-132 has since shown to play a role 
in dendritic spine formation [76]. Mir-138, another brain-enriched microRNA, was also shown to play a role 
in dendritic spine formation and maturation [77]. A bioinformatic study of  plasticity-related transcription 
factors and miRNAs has suggested that CREB is one hub of a regulatory network that comprises several 
microRNAs and the RE1 silencing transcription factor (REST). The analysis reveals that microRNAs and 
REST form a double negative feedback loop, and CREB acts as a positive regulator [78]. Such a circuit was 
later shown to regulate miR-9-2 during neuronal differentiation in vitro [79].
Certain microRNAs are known to be concentrated at the synapse and it has been suggested that they 
play a role in the regulation of local translation [70]. A large number of microRNAs have been shown by 
immunoprecipitation to be accociated with polyribosome complexes in neurons [80], and many of these 
are known to be synapse enriched [70]. Moreover, proteins such as FMR1, Dicer and Argonaute which 
are tightly coupled with microRNA biogenesis and action have been found in granules at the synapse 
[81, 82]. MicroRNAs also have role in the neurons beyond the direct regulation of synaptic function and 
plasticity. The microRNA cluster 17-92 and miR-9 have been shown to be critical for axonal outgrowth and 
development [83, 84].
Mir 34 family
One family of microRNAs that is particularly interesting in the context of learning, age-associated memory 
impairment and AD is the miR-34a/b/c family. MiR-34c in enriched in the murine hippocampus, and a 
large of overlap is seen when its targets are matched against a list of learning-related genes. Its levels 
are raised in human AD, as also in aged mice in the APP-PS1 mouse model of amyloid-induced learning 
impairment. Moreover, inhibiting miR-34c rescues memory impairment in mice [85]. MiR-34a is known to 
be raised in peripheral blood cells from AD patients [86]. This miRNA has also been reported as a marker 
of ‘brain aging’, with levels increasing concomitantly in the brain and in peripheral blood with aging [87]. 
Interestingly, miR-34a is relatively decreased in the brains of long-lived mice subjected to caloric restriction 
[88].  The underlying mechanism could be an evolutionarily conserved one, since miR-34 has also been 
implicated in age-associated neurodegenerative changes in Drosophila [89]. 
MicroRNAs-mRNAs regulatory network
Though most studies so far have focused on single microRNAs and their targets, most microRNAs have 
several predicted targets. Conversely, most genes have more than one microRNA binding site.  Mouse 
knockouts of Dicer, the enzyme critical for miRNA processing, have demonstrated that microRNA species 
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as a whole are essential to the survival of cells and organisms [90, 91]. However in many cases knocking 
out individual microRNAs leads to no or very minor deficits.  In C. elegans, where microRNAs were first 
discovered, a large scale deletion study revealed that the large majority of individual knockouts do not show 
an overt phenotype under basal condition [92]. In mice, two or more microRNAs must often be knocked out 
together before a phenotype can be distinguished, showing that they are functionally redundant [93, 94]. 
Mice with the miR-34 family deleted showed that the knockout has no effect on p53 responses, although 
p53 has been demonstrated several times in vitro to target miR-34 [95]. 
MicroRNAs are highly evolutionarily conserved, yet individual microRNAs appear to be functionally 
dispensable, with a few possible exceptions [96].  Quantititative proteomic approaches have shown 
that individual microRNAs regulate the expression of hundreds of proteins at at time, but each only to 
a small degree [97, 98]. For these and other reasons, a new theory of microRNA function suggests that 
most microRNAs exert a buffering effect rather than acting individually as direct and essential regulatory 
elements. The more traditional ‘tuning’ model of microRNA function suggests that microRNAs act to reset 
the expression of their target genes to a predetermined level through simple repression or through a 
feedback loop. By contrast the ‘buffering’ model suggests that microRNAs act to reduce fluctuation in gene 
expression [96]. The fact that microRNAs preferentially target genes that are have stable expression levels 
provides additional evidence for the buffering mechanism [99].
For this reason, in order to gain an understanding of underlying cellular mechanisms in disease, a genome-
wide approach to detect changes in the set of microRNAs seems appropriate. 
1.1.5 Mouse models in the study of learning and memory
A wide variety of model systems have been used for studying brain function including cultured cells, 
invertebrates such Drosophila, Aplysia, and C.elegans, as well as higher organisms like mice, rats, and 
primates. Each of these have a unique set of advantages and disadvantages. Rodents are especially 
popular models because they are small and easy to breed while maintaining a high degree of functional 
homology to humans at molecular, cellular and organ-system levels. Particularly relevant to the study of 
learning and memory, rodents are capable of displaying complex behavior, and various tests of learning 
and memory have been developed and tested in them. Further, the brain regions and the cellular circuits 
involved in some memory tasks have been studied in detail in mice and rats. The behavior paradigms 
we used in this study to assess learning and memory — the water maze task, the fear conditioning task, 
and the novel object recognition task (described in more detail in materials and methods) — are robust 
and reproducible tests, whose interpretation has been standardized through many years of observation. 
The Morris water maze navigation task tests the ability of mice to learn and remember the location of a 
platform hidden just underneath the surface of water in a pool [100]. Over several days, the escape latency 
or the time required to find the platform decreases as the mice learn its location. This is a hippocampus-
dependent task [101]. The fear conditioning task is a test of associative memory, that quantifies memory of 
an aversive stimulus by recording freezing behavior when mice are placed in the context associated with 
the stimulus. The fear conditioning task is thought to involve both the amygdala [102] and the hippocampus 
[103]. The novel object recognition task involves multiple brain regions and tests the ability of mice to 
recognize a previously seen object and differentiate it from a novel one [104]. While these are the 3 tasks 
used in this study, there are a large number of other tasks that have been designed to test various aspects 
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of rodent learning and memory.
However, mice clearly do not have the same range of cognitive and memory capabilities as humans and 
some of the higher cognitive and behavioral capabilities such as semantic or declarative memory can 
not be tested in mice. Mice also lack a prefrontal cortex, that is critical for complex behavioral planning 
and higher order functions in humans. Thus, in spite of their similarities in brain structure and molecular 
function, there are many critical differences behavioral and molecular results from mice can not be directly 
extrapolated to humans. 
In spite of their limitations, mice are a particularly useful model for the study of age-associated memory 
impairment in the context of this study. Like humans, mice show age-associated impairment in memory 
function [63, 105, 106]. Since aging is a long, continuous process the age-related deleterious effects 
seen on the brain and other organs are the result of many cumulative events. Both environmental and 
genetic effects play a role in aging. Since the aim of this study was to study the transcriptional changes 
associated with aging, we decided to eliminate the confounding factor of genetic variability. Mice were 
therefore a particularly useful model for this purpose, as a ready supply of inbred animals with virtually 
identical genotypes are readily available. Another advantage of using mice for this study was that their 
environment can be controlled to a great degree of precision, and factors such as stress which could 
contribute to cognitive changes can be carefully monitored. This is particularly relevant for the study of intra-
group variability, which forms a key part of the method we used
1.1.6 Genome-wide epigenetic and gene expression profiling as a method to study disease 
pathophysiology
Transcription of the genome into RNA is the first step to building the diverse and complex systems that 
comprise an organism. However, the vast majority of the human genome codes for sequences to which 
no function has been ascribed, and protein-coding genes form only a small fraction of the human genome 
[107]. Ribosomal RNA and transfer RNA are well known to be critical to transcription and translation, and 
as we begin to understand the function of other non-coding RNA (ncRNA) transcripts it becomes clear that 
RNAs such as microRNAs, snoRNAs, and long non-coding RNAs also play important regulatory roles. This 
regulation occurs both in trans-, such as by microRNA binding to complementary regions on mRNA and in 
cis-, such as by ncRNAs embedded in the 5’ UTRs or internal ribosomal entry sites of genes.
RNA is constantly transcribed from DNA and translated into protein. It is also subject to turnover by various 
intracellular mechanisms and the intracellular RNA profile is a dynamic index of the current state of the cell. 
Thus profiling the cellular RNA gives a snapshot view of not only the proteins which are poised for production 
but also of the regulatory or pathological cellular response mechanisms. The available RNA detected by 
any quantification method is thus controlled not only by the rate of transcription of that particular gene, but 
also by the stability of the transcript or the rate at which it is degraded. One of the earliest techniques used 
for the quantitative study of RNA was the Northern blot, where RNA is separated by electrophoretic mobility, 
transferred onto a membrane and then detected with a complementary fluorescent or electrochemically 
labeled probe [108]. Though this method is more cumbersome and less sensitive than the newer RNA 
quantification methods, it is has the advantage of high specificity, and unlike most newer methods, it does 
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not involve the reverse transcription and PCR amplification steps before detection [109]. The real-time 
PCR or qPCR method that is still arguably the most commonly used for RNA quantification involves cDNA 
synthesis by reverse transcription and then PCR amplification with real-time detection of the amplification. 
Quantification of qPCR data is usually relative, performed with reference to a housekeeping gene whose 
levels are assumed to remain constant. Thus ensuring the stability of expression of the reference genes 
in the specific experimental condition is critical to accurate quantification by this method [110]. qPCR is an 
extremely sensitive technique, and has been adapted for higher throughput experiments. Standardized 
or custom-designed qPCR arrays designed to simultaneously amplify hundreds of transcripts are now 
available and are commonly used in large-scale experiments [111, 112]. 
In the last 2 decades, there have been major technological advances in the techniques available to study 
transcription on a large scale. The phrase ‘genome-wide’ when used in the context of large-scale RNA 
studies usually refers to the microarray and Next Generation sequencing (NGS) techniques. Microarrays 
use chips spotted or printed at specific locations with thousands of oligonucleotide probes complementary 
to known RNA transcripts. After labeled cDNA binds to the probes, the amount of cDNA corresponding 
to a particular transcript can be quantified by fluorescence intensity at the relevant spot. While the 
microarray technique was the first to allow genome-scale studies of transcription, it is less sensitive than the 
amplification-based techniques and the minimum material required for microarrays can be a constraint to 
certain experimental designs. The advent of next-generation- or massively parallel sequencing has further 
accelerated the amount of RNA data that can be derived from a single experiment. This method is rapidly 
taking over from microarrays as the method of choice for genome-wide RNA profiling, by generating larger 
and larger volumes of data from decreasing amounts of starting material [113]. NGS reads the sequences 
in a given cDNA library by parallel de novo construction of complementary oligonucleotide sequences, 
followed usually by amplification and detection by fluorescent reporters. This “sequencing by synthesis” 
method is the most common but alternative NGS technologies exist that use other methods. 
Advantages and challenges in next-generation sequencing
 The greatest advantage of NGS over microarray techniques is that it uses a de novo sequencing approach. 
This allows the discovery and annotation of novel RNA, the detection of isoforms and partial transcripts, the 
study of repeat regions of the genome, as well as enables the study of post-transcriptional changes such 
as RNA editing [113].
NGS technology is currently still developing rapidly, with advances such as increased read length and 
lower requirements for starting material, enabling its application in a wider range of experimental settings. 
Moreover the rapidly decreasing costs of NGS experiments will likely enable this technology to be used 
not only in the research lab, but also in clinical diagnostics [114]. Two major advantages of genome-
wide approaches to transcription stand out. First, they allow an unbiased and exhaustive screening of 
transcriptional and epigenetic events associated with a biological phenomenon. This absence of an a priori 
selection bias for well-known or previously studied genes, has allowed researchers have been able to 
challenge existing dogma about important pathways associated with biological phenomena and led to 
the discovery of new types of non-coding RNA such as competing endogenous RNA and circRNA [115, 
116]. Second, the observation of a large numbers of concurrent transcriptional events allows us to better 
understand the interrelationships between genes. This provides a vast resource for the construction of 
intracellular regulatory network models.
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A special advantage of next-generation sequencing that is particularly relevant when studying RNA in 
special cellular compartments such as exosomes is that it allows for direct quantification of the number of 
RNA transcripts. Sequencing techniques are not completely free from bias caused by selective amplification. 
However, in a situation where there are no ‘housekeeping genes’ that can be used to normalize expression 
levels, sequencing provides a more reliable estimate than qPCR or arrays that are dependent on the affinity 
of individual probes to the RNA transcript.
When using these NGS to study transcription, the methods used for data analysis need careful consideration 
and can be critical to the results of the experiment. Raw data generated by the sequencer needs to be 
demultiplexed, checked for quality, and aligned to the genome of interest before a meaningful indication of 
RNA expression can be obtained. Many of these tasks are computationally intensive and require expertise. 
Algorithms for the mapping and counting of non-coding RNA have still not been standardized, and the 
development of new bioinformatic methods to tackle these challenges is ongoing.
However the challenges posed by the handling large amounts of data generated by high throughput 
sequencing technology are offset by its many advantages. 
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1.2 Molecular Mechanisms of Alzheimer’s disease (AD)
1.2.1 Alzheimer’s disease: Causes and hypotheses
Over the years, there have been a few different hypotheses to explain the etiopathogenesis of Alzheimer’s 
disease (AD), with lines of evidence to support each one.
The acetylcholine hypothesis, originating in the 1970s, suggests that there is a deficiency in cholinergic 
transmission in AD. This is based on post-mortem biochemical evidence from the brains of AD patients 
showing a deficiency in neocortical choline-acetyl transferase and presynaptic cholinergic deficit as well 
as a reduction in excitatory amino acid neurotransmission [117].  The majority of drugs currently used for 
treatment of AD (tacrine, rivastigmine, galantamine and donepezil) are are cholinesterase inhibitors, which 
attempt to increase the available of acetylcholine at the synapse.  However their therapeutic efficacy is low 
[118, 119].
The only other drug that is approved for AD treatment is memantine, which targets N-Methyl-D-aspartic 
acid (NMDA) receptors. This mode of action is based on excitotoxicity, where increased glutamatergic 
transmission leads to deregulated calcium influxes and apoptosis. Excitotoxicity as a pathological 
mechanism is common to several neurodegenerative diseases, as well as other CNS diseases such as 
stroke or traumatic brain or spinal cord injury. 
In the decades following its origin the cholinergic hypothesis was challenged, and the amyloid-beta (Aβ) 
and tau hypotheses took center stage. These are based on the accumulation of protein aggregates in the 
brains of patients with AD. The amyloid hypothesis is supported by the fact that familial AD is associated 
with mutations in the gene coding for amyloid precursor protein (APP) [120] and in the gene coding for a 
component of the gamma secretase (presenilin1 or PS1) [121] that cleaves APP. Human evidence for the 
involvement of the microtubule-associated protein tau comes largely from the aggregation of tau tangles 
in AD brains [122]. However mutations in tau are associated with frontotemporal dementia rather than AD 
[123]. In mice, there is a large body of evidence suggesting that reduction or knockout of the tau protein 
ameliorates Aβ-induced toxic decline [124]. 
An interesting recent hypothesis to that is beginning to emerge is that misfolded proteins can be transferred 
from cell-to-cell in a prion-like manner and spread disease pathology. The evidence for this is largely derived 
from mice and is as follows. First, the intracerebral innoculation of small amounts of AD brain extract can 
induce amyloidosis in human APP (hAPP) transgenic mice [125]. This effect is also seen when Aβ extracts 
are injected intraperitoneally, but not through other routes of administration [126], unlike in prion diseases. 
The tau protein may also be secreted from cells and spread across synapses [127-129]. On the cellular 
level, spreading of protein aggregates in manner that is similar but not identical to prions has been well 
documented [130, 131] and the spread of these protein aggregates (α-synuclein) in PD has been researched 
more than in AD. Aβ generated intracellularly has been shown to be released into the extracellular mileu 
with exosomes [132].  One major difference appears to be that in contrast to prions, there is no evidence 
that the protein aggregates associated with Parkinson’s disease (PD) or AD are infectious or spread from 
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person to person.  
In addition to these causal hypotheses, a multitude of other factors such as oxidative stress [133], metals 
and biometals [134, 135] is known to contribute to or increase the risk of developing Alzheimer’ disease.
AD — One disease or many?
For each of these proposed mechanisms, there exist cohorts of AD patients who do not fit the pattern, and 
show no evidence of the associated molecular pathology. At the time that the cholinergic hypothesis was 
being researched, it emerged that a subset of AD patients did not show significant cholinergic deficits [136]. 
Similarly, though ApoE4 is well known as a risk factor for AD, there exist geographically and ethnically 
distinct subpopulations of AD patients for whom ApoE4 has no association with AD [137, 138].
Moreover, Alzheimer’s disease is known to progress a differing rates after onset, and a variety of clinical and 
imaging indicators have been used to predict rates of decline [139]. However the reasons why some patients 
have slowly progressing disease and others deteriorate rapidly is unknown. Thus these mechanisms may 
coexist and more than one of them may cause the pathology that leads to disease manifestations such as 
loss of memory and other cognitive deficits.
Alternatively, rather than being a single disease characterized by all these features, what we know today 
as Alzheimer’s disease may well be a mixture of several diseases. This has been shown to be the case 
in carcinoma of the breast, which was initially thought of as a single disease, and classified into a handful 
of types based on tumor morphology and immunohistochemistry. With advances in genomic and gene 
expression studies it became clear that these each of these cancer types consist of several molecularly 
defined subtypes and that survival rates and response to therapy often depend critically on genomic 
classification [140].  These findings led to a new classification system, which is rapidly being adopted in 
clinical diagnosis and therapeutic decision-making.
This will perhaps one day be the case for other non-malignant diseases too and is one reason why 
molecular research into the gene expression patterns of AD may provide a clue to its pathogenesis or 
drive research into its classification. Since tissue for diagnosis is only available post-mortem, finding a way 
to study molecular mechanisms in humans, particularly the early mechanisms before neuronal loss could 
prove critical to stratifying disease and identifying effective treatment.
1.2.2 Age as a risk factor for AD — Parallels and contrasts between AAMI and AD
Aging is the single largest risk factor for Alzheimer’s disease, and it is well known that the prevalence 
of sporadic AD increases with age [132, 144]. Aging by itself, in the absence of clinically diagnosed 
AD is accompanied by varying rates of cognitive decline [145, 146]. Some of the individuals with age-
associated memory impairment (AAMI) will go on to develop dementia, while others will continue to show 
mild impairment [147]. Since aging and AD are so closely related, it is not clear which pathomechanisms 
underlie age-associated cognitive deficits in the absence of dementia and how they are different from those 
that predispose aged individuals to Alzheimer’s disease. 
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There are several lines of evidence indicating that the brain changes that accompany AD are different from 
those associated with AAMI. It has been shown by neuropathological methods that AD but not AAMI is 
associated with neuronal loss in the CA1 region [148]. In contrast, based on imaging studies in a several 
species, AAMI is thought to originate in the dentate gyrus of the hippocampus, with sparing of the CA1[148, 
149]. On the molecular level, levels of soluble versus insoluble Abeta1-40 and Abeta1-42 are thought to 
differentiate AD from AAMI [150].The ApoE4 allele that is an important genetic risk factor for AD. However 
its correlation with AAMI is unclear, with some studies supporting a correlation [151, 152] and others 
suggesting the opposite [153, 154].  
Based on rodent and primate studies it has been suggested that AAMI is accompanied by synaptic 
alterations and failure in the same synaptic circuits that are the sites of marked neurodegeneration and 
neuronal loss in AD [155, 156]. Functional magnetic resonance imaging (fMRI) studies show that AAMI is 
associated with a failure to suppress activity in task-irrelevant brain regions [157, 158]. This is supported by 
electroencephalography (EEG), and trans-cranial magnetic stimulation (TMS)  data, suggesting that age-
related cognitive impairments stem from an age-associated loss in the ability to suppress the processing 
of irrelevant stimuli or information [159]. The most recent evidence that AAMI is mechanistically distinct 
from AD comes from a microarray screen of gene expression profiles in post-mortem human brain tissue, 
which showed that changes in the expression of the histone binding protein RbAp48 could explain the 
phenomenon of accelerated memory loss [160]. 
It is clear that AD is different from AAMI, but it is equally clear that AD is rarely seen in the young in the 
absence of inherited mutations. However, little is known about the mechanisms that cause aging to be a risk 
factor for AD. One possibility is the cumulative effects of agents such as oxidative stress, which has been 
linked with both AAMI and AD [161]. 
1.2.3 Need for new methods to study Alzheimer’s disease
 
Alzheimer’s disease is diagnosed largely on the basis of clinical symptoms and a tissue -based diagnosis 
is clearly impossible. This has led to large efforts in the development of brain-imaging based technologies 
for AD diagnosis. However, for a deeper mechanistic understanding of the pathogenesis of AD, the 
development of new ways to study the live human brain is critical.
While there is clear evidence in humans from association studies for some of these mechanisms, such 
as the involvement of the amyloid precursor protein (APP), the association of the apolipoprotein 4 allele 
(ApoE4) [141], the bulk of the mechanistic studies have been performed in mice. One clear limitation of 
using transgenic mice as a model for the disease is that Alzheimer’s disease is a human disease, and 
there is no evidence that the specific pathogenic processes and response mechanisms exist in mice or 
other species. Another disadvantage is that behavioral tests in mice are relatively crude, there are few 
methods to detect subtle cognitive changes. Since the cognitive abilities that exist in mice (both for testing 
and that can potentially be impaired in a disease model) fall far short of humans, there is little reason to 
believe that mice can successfully be used as a model for the cognitive deficits in AD. The pathways and 
mechanisms involved in human AD, particularly the early cognitive deficits involving executive functions 
such as attentiveness, planning and abstract thinking [142], as well as language deficits, semantic losses 
and loss of vocabulary, confusion can scarcely be tested in mice. The types of memory tests that are 
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usually performed in mouse models are tests for associative and long term spatial memory, which are 
only a small part of the constellation of symptoms that accompanies advanced AD. This is perhaps one 
reason why drugs that are effective in halting disease progression and improving cognitive deficits in mice 
do not translate well to human disease. In mouse models of AD, which are largely based on the amyloid 
hypothesis, tau accumulation is not a consistent downstream component of the pathology [143]. This is 
a major difference from amyloid pathology in humans, suggesting that the toxicity of overexpressed Aβ 
in mice is mediated through different molecular mechanisms than in humans, and is therefore not an 
appropriate model to study human AD.
1.2.4 Current state of biomarkers in AD
Since the search for effective therapies for AD has yet to deliver drugs that succeed in reversing symptoms 
of modifying disease pathology,  it is possible that earlier diagnosis of the disease and insight into the 
early mechanisms of disease pathophysiology may aid in the search for more effective treatment. The 
symptoms of AD such as memory decline and confusion appear after losses in neuronal function and 
integrity have already occurred [162, 163]. Thus, by the time treatment is initiated, it is often too late to 
target any early, potentially reversible neuronal changes. Further, since most of our current knowledge of 
the disease etiopathology is based on post-mortem changes in the brain, our knowledge of the cellular and 
molecular events in early AD is relatively limited.
Since A-beta plaques and tau tangles are the traditional hallmarks of AD, they were also the earliest and 
best known biomarkers. Cerebrospinal fluid (CSF) levels of amyloid-beta 42 have been shown several 
times to be significantly lower in patients with AD [164-168].  Levels of tau protein in CSF are known to 
be raised in patients with AD [169, 170].  These 2 protein biomarkers in combination have been proven to 
have sensitivity rates of up to 95% in the diagnosis of AD [165]. However, their specificity is lower, with 36% 
of normal elderly subjects also testing positive  [165]. Since the first clinical studies on these biomarkers, 
longer-duration multicenter studies have proven that there are several factors such as the type of detection 
kit used and CSF storage conditions which can confound the analysis of these biomarker levels [171-
173]. Nevertheless, the use of CSF A-beta42 and tau levels is now recommended as a part of the clinical 
diagnostic workup in AD where possible, although they are neither sufficient nor necessary for establishing 
the diagnosis [174].
Certain neuroimaging markers are also able to differentiate between patients with AD and healthy control 
subjects. Magnetic resonance imaging (MRI) measurements of hippocampal volume have been used to 
predict progression from mild cognitive impairment (MCI) to AD [175] and with varying degrees of efficacy 
to differentiate AD from fronto-temporal lobar degeneration [176]. Fluorodeoxyglucose Positron Emission 
Tomography, which images glucose metabolism in various brain regions is able to localize areas of amyloid 
deposition in the cortex of patients with AD [177]. Technetium-99m single-photon emission computed 
tomography was able to differentiate patients with AD from those other kinds of dementia with an accuracy 
of about 75% [178].  These imaging procedures are also included in the latest revision of the recommended 
clinical procedures for AD diagnosis [174]. Other novel techniques for early detection of Alzheimer’s 
include non-invasive opthalmoscopic examination of the retina for amyloid plaques [179], and tests for 
olfactory dysfunction [180]. A recent study showed that ‘metabolomics’ or a liquid chromatography/mass 
spectrometry-based profiling of CSF or plasma for levels of metabolites such as amino acids, lipids, and 
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peptides could be used to detect a perturbation of metabolic pathways. This method was able to identify 
patients with AD or mild cognitive impairment from control subjects with a fairly high degree of accuracy 
[181]. 
The advantage of molecular markers over neuroimaging is that the former lend themselves better to longer-
duration multicenter studies, since tests can be performed at a later time after collection and preservation 
of the CSF or plasma sample. Further, the availability and costs of neuroimaging equipment coud restrict 
its widespread use in diagnosis.  Another advantage of molecular studies is that the candidate biomarkers 
can be used to further investigate underlying disease-associated mechanisms and to develop targeted 
therapies. Though there have been several candidates investigated for use as biomarkers for AD, the 
only ones which have been efffectively translated to clinical practice are A-beta and tau levels in CSF. 
Since these are based on traditional hypotheses of diease mechanism, they are unable to provide any 
new information about etipathogenesis of the disease. Thus there is plenty of room for the development of 









Figure 1.1 :Timeline showing the currently available biomarkers for 
Alzheimer's disease with pathological changes in the brain and clinical 
disease stages (Adapted from Perrin et al., Multimodal  techniques for diagnosis 
and prognosis of Alzheimer's disease, Nature 461(916-922) [177])
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1.2.5 Extracellular vesicles 
Most cells constitutively secrete exosomes and other types of vesicles into extracellular space. These 
vesicles may be derived from the intracellular endosomal system, in which case they are called ‘exosomes’ 
or may directly bud off from the plasma membrane. These extracellular vesicles (EVs) contain proteins, 
RNA and cell surface receptors derived from their cell of origin.  After the discovery in 2007 that cell-
derived secreted vesicles are able to transfer mRNA and microRNA between cells and that the mRNA 
transferred in this manner can function in recipient cells [182], there have been studies showing this to be 
the case in many different cell types such as hepatoctes [183], immune dendritic cells [184] glioblastoma 
cells [185], melanoma cells [186], monocytes [187], and embryonic stem cells [188]. In the 5 years between 
this discovery and the writing of this thesis, there have been a profusion of research and review articles 
describing the protein and RNA contents of cell-derived vesicles [189, 190].
The fact that cells secrete RNA and protein-containing vesicles that can be isolated from CSF is an untapped 
opportunity to study brain cellular processes. It is not yet clear if EV content is cargo intended for transport 
or other cells or unwanted byproducts of cellular processes, targeted for excretion from the cell, or both. 
In either case, EVs are rich in protein and RNA and studying these is likely to provide an insight into the 
functioning of the cell of origin.  In either case, there is increasing evidence that cells specifically target 
certain RNAs and proteins to EVs. 
1.2.6 Exosomes and extracellular vesicles in CNS physiology and Pathology
In the nervous system, evidence has rapidly accumulated in the last few years that exosomes and other 
extracellular vesicles play a role in physiology, in the healthy state as well as in disease. The importance 
of their role, and the extent to vesicle-mediated intercellular communication is critical to normal neuronal 
function is still being researched. 
1.2.6.1 Physiology
Secretion of exosomes and other vesicles into the extracellular space is a part of normal function in 
CNS cells. Neuronal and astroglial cells in primary culture constitutively secrete exosomal vesicles into 
extracellular medium and exosomal release can be regulated artificially by inducing cellular depolarization 
by potassium chloride treatment [191] or glutamatergic stimulation [192].  
The role of exosomes in intercellular communication in the nervous system has been best studied in the 
case of neuron-glia interactions. This interaction occurs in both directions, with glial exosomes being taken 
up by neurons and vice versa. Oligodendrocytes in culture secrete exosomes, which in addition to myelin 
protein components, contain several proteins that could be potentially neuroprotective [192]. The secretion 
of these oligodendroglial exosomes can be regulated by medium from neuronal cell cultures [193]. Further, 
a 2-way communication between neurons and oligodendrocytes has been demonstrated in cultured cells. 
Oligodendroglial exosomes are released upon glutamatergic neuronal stimulation, and neurons take up the 







Figure 1.2 : Scheme demonstrating cellular secretion of exosomes and membrane-derived vesicles 
These vesicles contain protein, RNA and cell-surface receptors, and can interact with the surface of 
recipient cells or be absorbed into them. The miRNA in these vesicles can act on mRNA in the recipient 
cells and regulate its translation.  Adapted from  F1000 Reports, Jul 2011, Exosomes: Secreted vesicles and 
intercellular communications Clotilde Thery, Institut Curie [206]
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exosomes [194]. Microglia-derived vesicles can modulate synaptic transmission by increasing neuronal 
excitability and enhancing sphingolipid metabolism [195]. 
Neuronal exosomes in which microRNA has been overexpressed are taken up by astrocytes and transfer the 
microRNA to the recipient cells, where it appears to actively elicit a response [196]. In addition to microRNA, 
it appears that the neuron-astrocyte exchange may also involve protein transfer. There are indications that 
astrocytes in culture release heat shock protein-containing exosomes, with the corresponding implications 
for the neurons and other cells in their microenvironment [197, 198]. The role of exosomes in interneuronal 
communication is yet to be studied in depth, but hints that they play a role in synapse physiology are 
beginning to emerge.  At the drosophila neuromuscular synapse, exosomes secreted at the presynapse 
are distinct from synaptic vesicles, and mediate trans-synaptic transfer of signaling proteins that are 
instrumental to synaptic development and plasticity [199].
The cell of origin of an exosome is usually suggested by receptors, surface protein or intravesicular proteins 
that it carries, such as Glu2/3 receptors suggesting a neuronal or glial source [191] or wnt-3 protein 
suggesting an embryonic stem cell source [200]. Traditional exosome isolation methods however yield a 
mixture of different exosome types. Immunostaining for different ‘cell markers‘ allows one to guess at the 
source of exosomes but does not provide an estimation of the relative proportion of cell types represented. 
Therefore, exosomes isolated from CSF or plasma are likely to originate from more than one cell type.  
Exosomal surface proteins have been used to target the delivery of exosomal contents to specific cells. 
In a landmark study, Alvarez-Erviti et al. engineered dendritic cell exosomes to express a neuron-specific 
peptide on their surface and were able to deliver a peripherally injected siRNA to the brain by packaging it 
in these exosomes [201]. Folate receptor-α, expressed on exosomes has also been used to deliver folate 
into brain parenchyma via CSF [202].
1.2.6.2 Pathology
There are several ways in which extracellular vesicles could be important in the pathogenesis or detection 
of CNS disease. Scattered evidence showing the role that EVs play in various neurodegenerative diseases 
is beginning to emerge. With relevance to AD, in APP-transfected N2A cells in culture amyloid beta peptides 
are released in part, in association with exosomes. Exosomal proteins such as flotillin and Alix colocalize 
with A-beta plaque sites in the brain [203]. Another connection between exosomes and AD is that AT270, a 
phosphorylated form of tau that is found in the CSF of AD patients with early AD is secreted from neuronal 
cells in association with exosomes [204]. 
Glioma cells containing an oncogenic variant of the epidermal growth factor receptor are able to transfer it 
via membrane-derived vesicles to cells which originally lacked this receptor. This results in a transformation 
of signaling pathways and a change in phenotype in the recipient cells [205]. In patients with glioblastoma, 
extracellular vesicles in the serum were found to contain mRNA corresponding to a tumor-specific splice 
variant [185]. This suggests that at least in malignancies, vesicles derived from pathological brain tissue are 
able to reach the blood stream and may be used for diagnosis. The existence of brain-derived vesicles in 
the blood stream in healthy individuals or in other CNS diseases like AD has not been proven. 
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For Parkinson’s disease, studies in an alpha-synuclein-secreting neuronal cell line showed that exosomal 
alpha-synuclein can cause disease pathology in healthy neuronal cells. Further, transmission of alpha-
synuclein pathology to healthy neurons transplanted into the brains of PD patients [206, 207], gave rise to the 
hypothesis that extracellular vesicles may be instrumental in the transport of α-synuclein aggregates from 
between connected neurons [208, 209]. Mouse motor neuron cells with mutated superoxide dismutase1 
(the mutation responsible for amyotrophic lateral sclerosis) also secrete it via exosomes. It has also been 
shown that prion protein is released in association with exosomes and this could be a mechanism by which 
prions are transferred from cell to cell [210]. 
Since studies so far suggest that EVs aid intercellular communication and potentially cellular excretion in 
the CNS, there is vast scope for further investigation into these vesicles and how their contents could serve 
as an indicator for processes occurring in brain cells. There is still much unknown about the contents of 
EVs, their relationship to host cells and the potential for their use in gaining a better understanding of CNS 






1.3.1 RNA in age-related memory impairment
Aging is associated with a deterioration of various physiological processes, and the loss of memory with aging 
is a well-known phenomenon. However, the deterioration in memory function is not uniform or predictable, 
and differs greatly from person to person, with some individuals showing rapid deterioration while others 
continue to perform well on cognitive tests at older ages. Most animal studies of age-associated memory 
impairment have studied the aged as a group rather than at the level of the individual. When using this 
approach, the mechanisms responsible for memory decline are masked by general aging-related changes. 
In order to investigate the heterogeneity in age-related memory loss and pinpoint some of the signs of 
healthy cognitive aging, the objectives of this study are:
1. Develop a mouse model that distinguishes benign age-related changes from those associated with 
cognitive decline
2. Test the model for reproducibility across age groups
3. Study the mRNA and microRNA expression profiles that characterize 'good' and 'poor' learners 
among aging mice
4. Determine which intracellular pathways are altered in age-related memory impairment
1.3.2 RNA in Alzheimer's disease
Alzheimer's disease is one of the most critical causes of disability in old age, and despite its high prevalence, 
no effective treatment exists. Like other diseases of the central nervous system, in Alzheimer's disease 
the currently available tools for investigation are limited to post-mortem study of diseased tissue and 
transgenic animal models. The recent discovery that cells secrete protein- and RNA-containing vesicles 
into extracellular space opens up new possibilities for studying disease mechanisms in inaccessible tissues 
such as the brain. The aim of this project was to to investigate the possibility that extracellular RNA in 
cerebrospinal fluid can be used to study Alzheimer's disease. The objectives of this study are
1. Determine if RNA exists in a stable form in human cerebrospinal fluid and can be reproducibly isolated 
from it.
2. To optimize the yield of RNA from CSF extracellular vesicles, and study the profile of cerebrospinal fluid 
RNA by next-generation sequencing
3. Compare cellular and extracellular RNA, determine if extracellular RNA serves as a readout for intracellular 
events
4. Investigate the potential for use of extracellular RNA as a biomarker for Alzheimer's disease





2.1 Animals and behavior experiments
2.1.1 Animal care
All mice except the APPPS1 transgenic animals were specific-pathogen-free C57Bl6/J wild type mice (Mus 
musculus, common house mouse) purchased from Janvier SAS. The APPPS1 mice also had a C57BL6/J 
background and were obtained from a colony maintained in-house. All animals were housed in the animal 
facility of the European Neuroscience Institute, Göttingen in individually ventilated cages (IVC, 32 × 16 × 
14 cm, Techniplast) with temperature and humidity regulated. They were fed and watered ad libitum with 
a standard laboratory mouse diet and cages were changed every seven days. The groups of mice used 
to test the inter-individual variability on the behavioral and molecular level (Project A) were all housed 
individually from the point of delivery onwards. All animal care and testing protocols were approved by the 
Veterinary Institute of the Lower Saxony State Office for Consumer Protection and Food Safety.
2.1.2 Water maze Task
A white square platform (11×11 cm) was placed in a circular pool 1.2 m in diameter, filled with opacified 
water at 20°C to a level 18 mm above that of the platform. Four different visual cues were attached around 
the tank and the mouse was gently placed in the water to look for the platform. Each mouse was allowed 
4 trials to find the platform, with a maximum of 60 seconds per trial.  If a mouse found the platform within 
60 seconds it was allowed to stay there for 10 seconds before starting the next trial. If a mouse did not find 
the platform in 60 seconds it was placed on the platform and allowed to remain there for 10 seconds before 
starting the next trial. This procedure was repeated on 5-10 consecutive days to allow the mice to learn the 
location of the platform. On the final day the platform was removed to perform a probe test for sixty seconds 
under the same conditions. The path taken by the mice was recorded by a video camera and analyzed by 
Videomot 2 software (TSE). For purposes of analysis the pool was divided into four quadrants, and probe 
test readout was the time spent in the quadrant where the platform was. The readout of learning from the 
training days was average escape latency or time required to find the platform across 4 trials [100].
2.1.3 Fear Conditioning Task
Each mouse was placed in a 23×23 cm metal cage (context) for 3 minutes before being subjected to an 
electric shock of 0.7 mA for 2 seconds administered to the feet via the metal bars at the bottom of the cage 
(TSE multiconditioning system). Associative learning was tested 24 hours later by exposing the mice to the 
same context for 3 minutes. The relative duration of freezing measured by the software (TSE FCS) using a 
motion threshold of 18 au and freezing time threshold of 1s was used as a readout for memory.
2.1.4 Novel object recognition test
The test involved three phases, an initial 2-day habituation phase, a subsequent 2-day similar-object 
exploration phase and a final day when a novel object was presented. The habituation phase involved 
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placing each mouse in an open chamber for 5 minutes each day. During the similar-object exploration 
phase, two identical blocks of size 3×3×3 cm were put in the chamber for the mouse to explore. On the fifth 
day one of the objects was replaced by an unfamiliar object. Based on the propensity of the mice to explore 
the novel object more than the familiar one, The recognition of novelty, and the resulting tendency to 
explore the unfamiliar object more than the familiar one is based on the memory of the familiar objects seen 
on the previous days. The movements of the mouse were tracked by a video camera (Videomot software) 
and the percentage of time spent exploring the new object was recorded for use as a readout [211].
2.1.5 Rotarod test
Motor impairment was assessed by placing the mice on a horizontal rod, rotating around its longitudinal 
axis (Rota Rod V4.02 System (TSE Systems)). The animals were trained for 2 days at a speed that would 
require them to cover 10 cm /s for 3 minutes 2 times each day. If the mouse fell off the rod during training, 
it was placed back on it repeatedly until 3 minutes had elapsed. The animals were then tested 4 times over 
2 days for 3 minutes, at speeds increasing from 5 cm/second to 180 cm/sec. The time elapsed before the 
mouse fell off the rod was automatically recorded and the average value obtained from 4 testing sessions 
was used an indicator of motor skills.
 
2.1.6 APPPS1-21 mice 
The APPPS1-21 double transgenic strain generated in the laboratory of Mathias Jucker at the Hertie-
Institute for Clinical Brain Research, Tübingen, Germany [212] was used as a mouse model of AD. The 
mice overexpress the gene for amyloid precursor protein (APP) with the ‘Swedish’ mutation (Lysine to 
Asparagine at position 670 and Methionine to Leucine at position 671) and the presenilin gene with a 
Leucine to Proline mutation at position 166 of the protein on a C57BL7/J background. The mutations, 
which are coexpressed under a neuron-specific Thy-1 promoter lead to early onset of neuropathology with 
cerebral amyloidosis detectable at the age of 6‒8 weeks [227]. 
2.1.7 Genotyping
DNA was isolated from mouse tail biopsies taken at about 3 weeks of age.  The tail biopsies were lysed 
in 200 μl of Direct PCR DNA Extraction Reagent (Viagen) with 2 μl proteinase K (200mg/ml) at 55°C for 
6 hours, followed by inactivation at 85°C for 45 minutes. The DNA was used for PCR under the following 
conditions: Denaturation for 5 minutes at 95°C followed by 30 cycles of 95°C for 30 seconds, 58°C for 1 
minute, 72°C for 1 minute and a final elongation step at 72°C for 5 minutes. The reaction mix contained 2.5 
μl of 10X Dreamtaq Green buffer (Fermentas), 1 μl of 10mM dNTP mix (Thermo Scientific), 1 μl of each of 
the 4 primers at 100um concentration, 0.05 μl of DreamTaq enzyme (Fermentas), 1-2 μl of genomic DNA 
and water to a total volume of 25 μl per reaction. The PCR products were run on an ethidium-bromide-
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containing 1% agarose gel with a size marker (Thermo Fischer Scientific). The primers for APP and PS1 
are in the table below
Name Sequence Product size (bp)
PS1 For CAG GTG CTA TAA GGT CAT CC 291
PS1 Rev ATC ACA GCC AAG ATG AGC CA 291
APP For GAA TTC CGA CAT GAC TCA GG 246
APP Rev GTT CTG CTG CAT CTT GGA CA 246
2.2 Cell culture and Exosomes
2.2.1 Primary neuron culture
Neuronal cell culture, A-beta treatment and exosome isolation were performed in the laboratory of Dr Anja 
Schneider, at the Max Planck Institute for Experimental Medicine, Göttingen. Cells from the hippocampus 
or cerebral cortex of C57Bl6/J mouse embryos at day 16‒18 were used to generate primary cultures. After 
euthanizing the pregnant female with carbon dioxide, the amniotic sac was dissected out and the embryos 
separated. After severing the head and separating the skull and meningeal coverings, the hippocampus 
or the cortex was dissected out under sterile Hank’s buffered saline solution HBSS. After completing the 
dissection at room temperature, hippocampal or cortex tissue from all the embryos in the litter was placed 
in a 15 ml tube with and 0.5 ml of 0.05% trypsin-EDTA (Gibco), and incubated for 10 minutes at 37°C. The 
trypsinization reaction was then stopped with Dubelco’s Modified Eagle’s Medium (DMEM) with 1% fetal 
bovine serum (PAA), 1% Glutamax (Gibco), 2% 50x B27 supplement (Gibco) and 1% Pen Strep (Gibco) 
for 5 minutes at 37°C, following which the mixture was pipetted up and through a glass pipette to obtain a 
single-cell suspension. After spinning at 1000g at 4°C for 10 minutes, the cell pellet was suspended in 1ml 
neuronal growth medium (Modified Eagle’s Medium (MEM), with 0.6% glucose, 0.2% sodium bicarbonate 
(Gibco), 1% 100X sodium pyruvate (Gibco), 1% fetal bovine serum (PAA), 1% Glutamax (Gibco), 2% 
50x B27 supplement (Gibco) and 1% Pen Strep (Gibco)).Viable neurons were counted using a Neubauer 
counting chamber after mixing 1 μl of cell suspension with 1 μl of trypan blue. The neurons were plated on 
10-cm dishes or in 12-well plates pre-coated with poly-L-lysine. The neurons were grown for up to 3 weeks 
in 10 ml or 1ml of neuronal growth medium in 10 cm dishes or 12-well plates respectively.
Before exosome isolation, the neuronal growth medium was exchanged for a smaller volume of serum-free 
exosome collecting medium (Dubelco’s Modified Eagle’s Medium (DMEM) with 1% Glutamax (Gibco), 2% 
50x B27 supplement (Gibco) and 1% Pen Strep (Gibco)) and exosomes were collected for 1 hour, 6 hours, 
or overnight as required. The collecting medium was subjected to the exosome isolation steps below. After 
removing the collection medium for exosome isolation, the cell were washed once with phosphate-buffered 
saline (PBS) before adding 0.5ml of Trizol to the plate or 200 μl of Trizol to the well. A cell scraper was then 
used to detach the cells from the surface and the cells were stored in Trizol until further processing for RNA 
isolation.
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2.2.2 Amyloid-beta treatment 
The Amyloid-beta 42 (Aβ42) oligomers and Amyloid-beta 4 (Aβ40) monomers were obtained from the 
laboratory of Dr Markus Zweckstetter at the Max Planck Institute for Biophysical Chemistry, Göttingen. 
Oligomers or monomers were prepared in a stock solution of 100um in 10X phosphate buffered saline 
and used at a final concentration of 10 um. Primary hippocampal neurons in 10-cm dishes (4 dishes per 
condition) were treated  with Aβ42 oligomers, Aβ40 monomers, and vehicle at day 15 in vitro After overnight 
treatment, one set of dishes was used for the MTT assay, and exosomes and cells from the remaining 3 
dishes per condition were used for RNA isolation.
MTT assay
Thiazolyl Blue Tetrazolium Bromide (Sigma), at a concentration of 5mg/ml in PBS was used for the MTT 
assay. After treatment with A-beta, the A-beta- or vehicle-containing medium was replaced with 3 ml of fresh 
medium per 10-cm dish and 300 μl of MTT solution was added. After incubation for one hour at 37°C, the 
medium was pipetted off and 3 ml DMSO added. After shaking for 20 minutes at room temperature, 100 μl 
of the solution was transferred to a 96-well plate in triplicate. An ELISA plate reader was used to quantify 
the assay colorimetrically at a wavelength of 570nm.
2.2.4 Exosome Isolation
Exosomes were isolated from fresh cell culture medium, or frozen cerebrospinal fluid or plasma. When 
isolating exosomes from cultured cells, cellular growth medium was exchanged for a lower volume of fresh 
‘collecting medium’. The cells were grown in the fresh medium for 1 hour, 6 hours or overnight, as required 
and this time was called ‘collection time’, after which the medium was harvested and used for exosome 
isolation.
The following protocol was used to isolate exosomes from cell culture medium, cerebrospinal fluid or plasma. 
The fluid was subjected to serial centrifugation at 3500g for 10 minutes, 4500g for 10 minutes, and 10000g 
for 30 minutes, with the supernatant collected each time and pellet discarded. The 10000g pellet from CSF 
and plasma was saved and processsed as the microvesicle fraction. Finally the supernatant was subjected 
to ultracentrifugation at 100000g to obtain the exosome pellet and the exosome-free supernatant. The 
exosomes were resuspended/lysed in 200 μl TRI-reagent (Sigma) and stored at -20˚C until RNA isolation.
2.3 Cerebrospinal fluid and plasma from patients
Cerebrospinal fluid for exosome preparation was obtained from 18 AD patients and 20 controls. The AD 
patients were all from the Göttingen University Hospital. Of the control samples, 14 were obtained from the 
same source and the remaining six were obtained through Dr Brit Mollenhauer from the Paracelsus Elena 
Clinic, Kassel. The control samples were from patients suffering from other neurological and psychiatric 
disorders. Analysis of patient CSF was approved by the ethical committee of the Medical Faculty, University 
Medicine Goettingen (IRB 02/05/09) .
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Individual patient details and a summary of patient characteristics can be found in tables 1 and 2. After CSF 
withdrawal via lumbar puncture, the standard operating procedure was to centrifuge the sample as soon 
as possible at 3000g for 10 minutes to remove any cells or cell debris. The supernatant was then frozen 
and saved at -20°C until exosome isolation. In all cases a volume of 2 ml of CSF or plasma was used for 
isolation of exosomes.
2.4 RNA Isolation and profiling
2.4.1 RNA isolation from exosomes, tissues and cultured cells
All RNA samples were isolated using TRI-Reagent (Sigma-Aldrich),except when otherwise specified. The 
sample (dissected tissue, or exosomes/microvesicle pellet) was thoroughly homogenized in 1ml TRI-
Reagent and incubated at room temperature for 5 minutes. In cases where low RNA yield was expected, 
such as exosomes, microvesicles or volumes of tissue, 2 μl of 25ug/ul glycogen was added with trizol.  200 
μl of chloroform was then added and mixed by vigorous shaking, followed by a second 5-minute incubation 
step at room temperature. The mixture was centrifuged at 12000 rcf for 15 minutes until phase separation 
and the topmost aqueous RNA-containing layer pipetted into a new 1.5 ml tube. The RNA was precipitated 
using 500 μl of isopropanol overnight at -20˚C. After centrifugation at 12000rcf for 30 min the supernatant 
was discarded and the pellet washed 2 times (12000 rcf for 5 minutes each) with 75% ethanol. The RNA 
pellet was air-dried and resuspended in 30-50 μl of water, depending on the expected RNA yield. For 
exosome isolation, the RNA was resuspended in 10 μl of water.   
RNA from brain tissue was quantified using a NanoDrop spectrophotometer, For RNA from exosomes, 
total Eukaryotic pico 6000 RNA assay (Agilent) and the corresponding RNA 6000 PicoChips were used 
to quantify RNA and study its profile on a 2100 Agilent Bioanalyzer microfluidics platform according to the 
manufacturer’s instructions.
2.4.2 cDNA synthesis and qPCR
For microRNA real-time PCR, cDNA was synthesized using the miScript II RT kit (Qiagen) using the supplied 
protocol. The SYBR green-based miScript qPCR system (Qiagen) was used for real time PCR. Reactions 
were carried out in a reaction volume of 10 μl using predesigned microRNA-specific assay primers (Qiagen) 
and cDNA at a dilution of 1:200. RNU6B was used as a reference small RNA and the standard amplification 
protocol for microRNA was denaturation at 95°C for 5 minutes, followed  by 40 amplification cycles at 94°C 
for 15 seconds, 55°C for 30 seconds, 70°C for 30 seconds and a cooling step at 40°C for 30 seconds.
For mRNA real-time PCR, cDNA was synthesized using the Transcriptor First Strand cDNA synthesis kit 
(Roche). The TaqMan reactions were carried out in a volume of 25 μl using selected automatically designed 
primers from the Universal ProbeLibrary (UPL) assay design center, the corresponding UPL fluorescent 
probes (Roche),  LightCycler 480 master mix and cDNA at a dilution of 1:5. HPRT1 (mouse) or GAPDH 
(human) was used as a reference gene and the standard amplification protocol was denaturation at 95°C 
for 5 minutes, followed  by 40 amplification cycles at 95°C for 10 seconds, 60°C for 30 seconds, 72°C for 
1 second and a cooling step at 40°C for 30 seconds. All qPCR reactions were carried out in a LightCycler 
480 instrument (Roche), analyzed using the accompanying LightCycler 480 software with the delta-delta 
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Ct method used for quantification.
Library preparation 
Small RNA libraries were prepared from total RNA using the TruSeq small RNA sample preparation kit 
(Illumina) according to the manufacturer’s instructions.  When relatively plentiful amounts of RNA were 
available as in the case of hippocampal tissue, 100 ng of total RNA was used as starting material. In the 
case of exosomal RNA, lower amounts were used, as described in detail in section 3.2.5.
2.5 Bioinformatics and statistical analysis
2.5.1 Primary and secondary analysis of next-generation sequencing data
The processing of data produced by the HiSeq sequencer up to the generation of mRNA or non-coding 
RNA reads was performed by the group of Dr Stefan Bonn at the NGS facility of the DZNE, Göttingen. A 
customized software pipeline was used, consisting of the following steps. For mRNA,  the CASAVA 1.8.2 
software (Illumina) was used for demultiplexing and quality control, followed by BOWTIE2 for alignment to 
the human or mouse genome [212], and HTSeq for read counting. For microRNA and other non-coding 
RNAs, after demultiplexing and quality control, the basic local alignment search tool (BLAST) [213] was 
used for alignment to MiRBase version 19,with a cutoff score of 5 × 10-7 and single mismatch allowed. The 
remaining reads were mapped to the non-coding RNA database fRNAdb version 3.4. 
2.5.2 Statistical and functional analysis of next-generation sequencing data
The R environment, and various user-contributed R packages was used for statistical analysis and 
visualization of the read count data sets, as detailed below. The DESeq package [214] was used to obtain 
lists of mRNA or microRNAs differentially expressed between groups. Heatmaps were generated using the 
ggplot2 package. The machine learning algorithms Random Forest and Support Vector Machines were 
implemented using the R packages randomForest and e1071 respectively.
Microsoft Excel was used to calculate Pearson correlations and p values for matrices of gene and microRNA 
expression levels in individual mice. Graphpad prism version 6 was used for analysis and visualization 
of behavior data, qPCR results, and individual RNA read count correlations. The GSEA algorithm was 
implemented using the desktop Java application javaGSEA. A list of gene symbols and corresponding 
correlation p values was submitted in the required .rnk format to the GseaPreranked tool. For gene ontology 
(GO) analysis, the GO gene set collection (c5) from the Molecular Signatures Database version 4.0 was 
used. For analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways the curated KEGG 
collection (c2) was used, from the same database. The entire list of GO categories obtained by GSEA with 
the corresponding false discovery rates were submitted to the REVIGO online tool to create a visualization 








3.1 Age-associated memory impairment
The degree of age-associated memory impairment varies highly between individuals. Thus within a group 
of aging people, there are some who retain good cognitive skills, while others show a decline. One of the 
aims of the work described below was to test if this intra-group homogeneity and its molecular correlations 
could be modeled in mice. This would allow us to differentiate between general age-associated changes in 
the brain and age-related changes that have a connection with memory impairment.
3.1.1 Aging is associated with increased variability in water maze task performance
In order to study the effects of age on intra-group variability in mice, individually housed and identically 
treated C57Bl6J mice at the ages of 3 months (young adult, n = 12),  and 16 months (early aging, n = 12) 
were trained in the hippocampus-dependent Morris water maze memory task.
Learning and memory performance was analyzed in different groups of mice over a period of 10 days. 
As expected, the old mice showed a learning impairment, indicated by increased escape latency or time 
required to reach the hidden platform (Fig 3.1.1A). When the performance of mice in both groups is plotted 
individually (Fig 3.1.1B) a marked difference in variability within groups is evident. While the young mice 
cluster tightly together by performance, individuals within the group of old mice perform very differently from 
one another. The group of old mice is thus composed of individuals that are able to perform on par with 
the young mice as well as individuals with varying degrees of impairment. This variability was quantified 
using the F test for equality of variance, confirming that for most of the tested days the 16-month-old group 
showed a significantly higher intra-group variance than the 3-month-old group.
To demonstrate that variability increases progressively with age, additional groups of mice at the ages 
8 months (adult, n = 12) and 12 months (middle-aged, n = 12) were trained in the water maze task for 4 
days, and a cross section of WM escape latency in these 4 groups is depicted in (Fig 3.1.1 C). Again, when 
plotted individually, an age-dependent increase in variability within groups is observed, and quantified using 
the F test for equality of variance (Fig 3.1.1D).
3.1.2 No increase in variability on other learning tasks, visual or motor skills
The 3- and 16-month old groups of mice were subjected to a battery of additional behavior tests to study 
impairment and variability on other cognitive measures. When performance was tested by the probe test, 
a test for long term spatial recall, carried out on the last day of the water maze task, the young mice spent 
significantly more time than the old mice in the target quadrant, where the platform had been placed over 
the training period (Fig 3.1.2A). Though the old mice were significantly impaired, there did not appear 
to be a difference in variability between the 2 groups (Fig 3.1.2A). Similar results were observed on the 
fear conditioning test, an associative memory test, where the mice are trained to associate an aversive 
stimulus with a given context. The young mice displayed a significantly higher level of freezing than the 
old mice when placed back in the context (Fig 3.1.2B), indicating that the development of associative 
fear memory was impaired in the old mice. As with the probe test, there was no difference in variability 
between the groups (Fig 3.1.2B). The third behavior test performed on these groups was the novel object 
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Figure 3.1.1 :Aging is associated with increased variability in water maze task performance
A:  Group performance of old(16-month-old) and young(3-month-old) mice on the training days of the 
Morris water maze task. (N = 12 per group, student's two-tailed T test p value = 0.0011, <0.0001, <0.0001, 
0.0044, 0.0061, 0.0138, 0.0823, and 0.0059 on days 2, 4, 5, 6, 7, 8, 9  and 10 respectively), B: Individual 
performance of  old(16-month-old) and young(3-month-old) mice on the training days of the Morris water 
maze task(N = 12 per group, F test for equality of variances, p value = 0.0041, 0.8037, 0.0002, 0.0057, 
0.0048, 0.0023, 0.0019 and 0.0004 on days  1, 2, 4, 6, 7, 8, 9 and 10 respectively), C: Cross section on 
day 4 of the water maze test, showing group performance at the age of 3,8,12 and 16 months (n = 12 per 
group, student's T test p values: 3 versus 12 months = 0.0025 and 3 versus 16 months < 0.0001)D: Cross 
section on day 4 of the water maze test, showing individual performance at the age of 3,8,12 and 16 months 
(n = 12 per group, F test for equality of variances  p values: 3 versus 8 months =0.03, 3 versus 12 months 


































































































































































Figure 3.1.2 No increase in variability on other learning tasks, visual or motor skills
Other behavior tests :Performance of 3- and 16-month old mice( n = 12 per group) on the water maze 
probe test(A),Fear conditioning task(B),novel object recognition task-short term memory (C) and novel 
object recognition task-short term memory (D). Each circle represents an individual animal. Mean is 
represented by a black horizontal line. (student's two-tailed T test p value = 0.0077 for probe test and 
0.0023 for fear conditioning task.)
Visual and motor skills: Performance of 3- and 16-month old mice( n = 12 per group) on the visible 
platform probe test(E),swim speed(F), and rotarod test (G).  Each circle represents an individual animal. 
Mean is represented by a black horizontal line
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recognition test, which evaluates the ability to learn and remember objects previously explored. This test 
was performed to test both long-term and short term memory in the 2 groups of mice. The readout for the 
test is the time spent exploring the novel object, which did not differ significantly between groups, either 
long-term or short term (Fig 3.1.2 C and 3.1.2D). Similarly there was no difference in variability between 
groups (Fig 3.1.2C and 3.1.2D).
Since aging is accompanied by motor and visual deficits which could potentially influence the effects of the 
learning and memory tests 3 tests for sensorimotor skills were carried out in these 2 groups of animals. 
Two of these tests were within the context of the water maze task — the visible platform probe test, where 
the underwater platform is flagged tests for visual impairment, and the swim speed test detects difficulties 
in swimming that could hamper water maze performance. The third test was the rotarod test, which tests 
balance, coordination, motor planning and general physical condition. On all three tests, the aged group 
performed no differently than the young group (Fig 3.1.2E, F and G) and there was no difference on 
variability between groups, indicating that at 16 months of age, the mice show no motor or visual deficits 
that could account for impaired performance on the cognitive behavior tests.
3.1.3 Individual performance on behavior tests is consistent
3.1.3.1 Individual performance on the water maze task is consistent
Since mouse performance varies within the group of animals at the same age, especially for aged mice, 
the question that arises is how consistent are the aged and young mice in their learning abilities from day 
to day. Are the mice that find the platform quickly on the first day of water maze training the same ones that 
do so on day 2, day 3 and the other testing and training days? Similarly, in the group of old mice, are the 
impaired learners impaired throughout the duration of the task, or are there high inter-day fluctuations in 
individual performance? In order to answer these questions, correlations between water maze performance 
through the various days of the task were measured in groups of male mice at the ages of 3 months (n = 
30), 12 months (n = 23) and 16 months (n = 23) (Fig 3.1.3).
For each age group, correlations between escape latency on days 2,3, and 4 of the task were measured 
and are displayed as scatter plots (Fig 3.1.3A, B and C). For the group at 3 months of age, data are also 
available for days 5 and 6 (Fig 3.1.3 D). An additional measure of water maze spatial learning is the 
probe test, and the readout for the probe test is time spent in the platform quadrant. For the probe test, 
better performance is gauged by longer time spent looking in the correct quadrant. Correlations were also 
measured between probe test performance and average performance throughout the water maze training 
days as well as between probe test performance and water maze escape latency on the last day (day 
before probe test) (Fig 3.1.3D). The squared Pearson’s correlation coefficient (R2) and the corresponding 
p value are used to quantify the correlation. From the tables in Fig 3.1.3, it is clear that for almost all the 
days tested and at all ages, there exist statistically significant positive correlations in mouse performance 
between days. In case of the probe test, the correlations are negative (negative R values), meaning that 
longer time searching in the correct quadrant during the probe test correlated with short escape latencies 
on the training days. 








































































Water maze days Swim speed
A B C
D E
Figure 3.1.3.1 Individual performance on the water maze task is consistent
A: Correlations between water maze escape latency on day 3 ( horizontal axis) and water maze escape 
latency on days 2 (light circles) or  4(dark circles) in groups of mice at the ages of 3 months(A, n = 30), 12 
months(B, n = 23), and 16 months (C,n = 23). Deming regression lines are indicated on each plot and each 
solid circle represents an individual animal., D: Tables showing correlation between water maze paramaters 
on various days in groups of mice at the ages of 3 months(n = 30), 12 months(n = 23), and 16 months (n 
= 23). Statistically significant p values shaded in grey, E: Tables showing correlation between water maze 
parameters and swim speed in groups of mice at the ages of 3 months(n = 30), 12 months(n = 23), and 16 
months (n = 23)
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latency or time in target quadrant and individual swim speed (Fig 3.1.3E). There were no correlations 
either positive or negative between swim speed and the indexes of water maze spatial learning at any 
age (Fig3.1.3E).  This finding shows once again that water maze performance at the ages tested is not 
influenced by sensorimotor abilities or impairment.
Thus the repeated finding in various age groups on water maze task performance allows us to conclude 
that the water maze task can be reliably used to distinguish aged individuals with impaired spatial learning 
ability from those who retain the ability to learn and recall spatial information even as they age.
3.1.3.2 Individual performance on the fear conditioning task is consistent
After establishing for the water maze spatial learning task that distinct ‘good learners’ and ‘poor learners’ 
exist within the group of animals at the same age, we checked if similar correlations were present in other 
tests of mouse learning and memory — fear conditioning extinction and the novel object recognition task.
The fear conditioning extinction protocol, performed on the days immediately following the fear conditioning 
task, consists of placing the mice back in the fear-associated context for 3 minutes each day over several 
days. It can be observed that normal individuals will show less freezing behavior as the days pass, a 
phenomenon that is called fear extinction [216]. This behavior has been attributed to ‘new learning’, where 
the mice acquire a competing memory that the context is safe, and to habituation to the context [216]. 
Both the fear conditioning task and the fear extinction protocol use freezing behavior or percentage of time 
spent freezing as their readout. In a group of mice at the age of 3 months (n = 30) correlations between 
freezing behavior and extinction behavior were measured over 4 days after fear conditioning (Fig 3.1.3.2 
A and B). After the aversive stimulus, there are high individual correlations in time spent freezing on the 
fear conditioning test day and through the extinction days. The mice that spend the longest time freezing 
when tested in the context 24 hours after the aversive stimulus tend to show a slower extinction of this fear 
memory and continue to show high freezing throughout the extinction protocol. Further, at both 3 months 
and 12 months of age, prestimulus freezing or baseline freezing before exposure to the aversive stimulus 
show correlations with post-stimulus freezing behavior. 
3.1.3.3 No correlations exist between performance on different memory tasks
The water maze task and the fear extinction protocol are multi-day tests, which lend themselves very well 
to the analysis of individual performance at different time points. The third test performed on the groups 
of animals at the ages of 3 (n = 30) and 12 months (n = 23), the novel object recognition task studies 
exploratory behavior, short term memory and long term memory. 
In order to compare individual performance on all these 3 tests, correlations in inter-individual performance 
between the 3 different tests were measured. (Fig 3.1.3.3). There were no correlations between performance 
on water maze and performance on either fear conditioning or novel object recognition. Similarly, no 
correlations between the fear conditioning and novel object recognition task performance were observed 
(Fig 3.1.3.3). These results suggest that performance on one memory test is not predictive of performance 
on other tests and that impairment in the learning mechanisms involved in spatial, associative and other 























Fear conditioning - Freezing time correlations
A B
Overall, at the early-aging time point of 16 months, since the water maze task showed the widest spectrum 
of intra-group variability (Fig 3.1.1) and seemed a robust method to distinguish between poor and good 
learners (Fig 3.1.3). Therefore this task was chosen for further investigation into the molecular mechanisms 
underlying the variability in age-related learning and memory impairment.
3.1.4 Gene expression in aging mice
Figure 3.1.3.2 Individual performance on the fear conditioning task is consistent
A: Correlations between time spent freezing on the first day of exctinction (horizontal axis) and time spent 
freezing when testing fear memory (light circles) or  on the second day of exctinction (dark circles) in 
a group of 30 mice at the age of 3 months(A, n = 30). Deming regression lines are indicated and each 
solid circle represents an individual animal, B:  Tables showing correlation between the pre-stimulus and 
poststimulus freezing behavior in mice at the ages of 3 months(n = 30) and 12 months (n = 23).
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Figure 3.1.3.3 No correlations exist between performance on different memory tasks
Legend: A: Correlation between relative time spent exploring novel object in the novel object exploration 
task (horizontal axis) and average water maze escape latency over all tested days (vertical axis) B: 
Correlation between freezing time as a percentage of total time (horizontal axis) and average water maze 
escape latency over all tested days (vertical axis) C: Correlation between freezing time as a percentage of 
total time (horizontal axis)and  relative time spent exploring novel object (vertical axis). Deming regression 
lines are indicated and each solid circle represents an individual animal, n = 30, age = 3 months).Tables 
showing correlation between parameters on the water maze and fear conditoning (D), water maze and 
novel object recognition tasks (E) and fear conditioning and novel object recognition tasks (F) in mice 
at the ages of 3 months(n = 30) and 12 months (n = 23).
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Having established that the water maze task can be used to reproducibly estimate the level of learning 
impairment in aging mice, the next step was to study the molecular changes associated with this impairment. 
Since the hippocampus is closely connected with both spatial learning and memory formation (See section 
1.1.1), the method chosen for this was transcriptome and microRNAome profiling of the hippocampus.  
A group of 22 mice at the age of 16 months was subjected to the water maze task for 4 days and the 
probe test was performed on day 5.  Mouse behavior was scored by performance on the probe test of 
the water maze. On this test, the time spent searching in the correct quadrant is an index of how well 
the mice were able to learn the task, with higher time spent indicating stronger learning. After confirming 
that there were significant correlations in inter-day performance within the task, the mice were sacrificed 
2 weeks after the day of the probe test. Next generation sequencing was performed on RNA isolated 
from the hippocampi of these mice. Since the behavioral performance of the mice lies along a spectrum, 
each mouse was represented as an individual and tissue and RNA processing and data analysis were 
performed accordingly. Hippocampal gene expression was then correlated with individual performance on 
the water maze probe test (Fig3.1.4). In order to perform this analysis, Pearson product-moment correlation 
coefficients were calculated between normalized gene expression counts for all expressed genes and 
probe test performance of the individual. Of all the expressed genes, 765 showed a significant positive 
correlation with performance and 391 showed a significant negative correlation (Fig 3.1.4C and D) with 
performance (unadjusted p values <0.05). 
3.1.5 Gene sets that correlate with memory performance
In order to derive biological meaning from the gene lists obtained by correlating behavioral data with gene 
expression data, the gene set enrichment analysis (GSEA) method was used. GSEA is a computational tool 
initially developed for the analysis of microarray data when genome-wide expression profiling started to gain 
popularity [217]. The traditional method of extracting biologically relevant information from expression data 
involves choosing a differential expression fold change value and/or a p value as a cutoff point for preparing 
a shortlist of genes. This shortlist, with all genes weighted equally regardless of original p values or fold 
change, is then submitted to a tool that detects significant biological pathways or ontologies. In contrast, the 
GSEA algorithm is designed to analyze entire sets of genes associated with biological processes. GSEA is 
typically used on the complete genome-wide expression data, and the genes are weighted by their degree 
of dependence on the biological process being analyzed, such as by level of fold change.  The algorithm 
then calculates enrichment scores for gene sets, based on the ranking of genes within that gene set in 
the experimental data. The level of statistical significance of the gene set is then calculated and adjusted 
for multiple testing [217].  This powerful analytical method is now being used for gene expression data 
obtained by NGS [218].  
GSEA is particularly well suited to the analysis of the gene expression in the aging mice used here for two 
reasons; first — the correlation analysis used to obtain lists of important genes provides no fold-change 
values and second — using a cutoff of 0.05 on p values after adjusting for multiple testing leaves too few 
genes for a meaningful analysis. The nature of the experiment, which aims to detect small gene expression 
changes in genetically-identical individuals within a group of animals at the same age thus necessitates a 
highly sensitive analysis approach.
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Figure 3.1.4 Gene expression in 16-month old mice
A; Time spent in target quadrant by 16-month-old mice( n =22), plotted individually and sorted from worst 
performace to best performance, Heat maps showing the scaled, normalized expression values of the 100 
genes most significantly correlated positively (B) and negatively (C) with performance on the probe test. Color 
scale represent levels of expression, with blue representing highest expression and red representing the 
lowest expression, D: Heat map showing expression values of 100 randomly selected genes, E. Examples of 
correlations between performance and gene expression for the genes ETS domain-containing protein-3(Elk3), 
RNA binding motif protein-48(Rbm48), and Eukaryotic Translation Initiation Factor 4E3 (Eif4E3) which correlate 
positively with performance, and  Glutamate receptor subunit epsilon-4 (Grin2D), Mas-related G-protein 
coupled receptor member E(Mrgpre) and Calsyntenin3 (Clstn3) whose expression correlates negatively with 
performance. The gene expression levels are plotted as normalized read counts on the vertical axis versus the 
probe test performance (percent time spent in target quadrant) on the horizontal axis.  Deming regression lines 
are indicated and each solid circle represents an individual animal, (n = 22).
Figure 3.1.5 Gene sets that correlate with memory performance (Facing Page)
A: Graph showing number of GO-terms and KEGG pathways significantly enriched in the original correlation 
dataset (Red) and after 3 independent permutations of the data set (black). B: Tables showing enriched GO-
terms and KEGG pathways C: Graphical representation generated by the REVIGO tool of the molecular 
function GO categories.The enriched GO terms  are represented on the graph as circles, with the most 
signifcantly enriched terms labeled. The color of cirlces represents enrichment scores, with red represeinting 
the most enirched in the positive direction and blue representing the most enriched in the negative direction. 
The horizontal axis also represents enrichment score and terms are organized vertically by their semantic 
similarity or  degree of relationship. 
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The entire list of genes expressed in the 16-month-old mice, ranked by correlation score was analyzed by 
GSEA, for enriched gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways. GO terms provide information about the molecular functions and cellular compartments of the 
gene expression products [219] while KEGG pathway analysis gives an indication of which biological or 
disease-relevant pathways the genes may be involved in [220].  The GO terms 'structural constituent 
of ribosome', 'RNA binding', 'endosome', 'mitochondrial envelope', 'mitochondrial membrane', 'cellular 
respiration', 'translation', and 'cellular biosynthetic process' emerged as significantly associated with 
good performance (false discovery rate < 10%). KEGG pathway analysis gave very similar results, with 
'ribosome'  and 'oxidative phosphorylation' being the most highly enriched pathways (Fig. 3.1.5B). The GO 
terms associated inversely with good learning were 'glutamate receptor' and 'glutamate signaling pathway'. 
No KEGG pathways inversely associated with good learning were detected at the cutoff values chosen 
(false discovery rate < 10%).
To estimate the possibility of false positives generated by the above procedure, the procedure was repeated 
twice with random permutations of the behavioral data. When the genes and correlation values derived 
from the permuted correlation analysis were analyzed by GSEA, a far lower number of GO terms or KEGG 
pathways emerged as statistically significant (Fig 3.1.5A).  
3.1.6 Over- and under-expressed pathways in high-performing aged mice
After deriving a list of enriched pathways and biological functions in the high-performing animals, the 
individual gene expression levels of genes in the corresponding pathways were revisited.
The genes in the pathways ribosome/RNA-binding/translation, enriched in the animals who continued to 
perform well on the water maze task despite their age were studied further by comparing their expression 
levels in the 3 best- and worst-performing individuals.
Gene set enrichment analysis revealed a striking enrichment in genes in the GO category structural 
'constituent of ribosome', and the KEGG pathway 'ribosome'. Both these gene sets contain ribosomal 
proteins that associate with rRNA to form the 40S and 60S eukaryotic ribosomal subunits. As seen from (Fig 
3.1.6A and B) a large proportion of the genes encoding ribosomal proteins in both subunits are expressed 
at higher levels in 'good learners' than in the 'poor learners'. 
Gene expression levels of translation and ribosome-related genes in the top and bottom 3 animals are 
shown as part of the translation initiation pathway (Fig3.1.6B). This pathway was used for visualization to put 
the relationships between the components of the translational machinery into perspective. From Fig 3.1.6B 
it is clear that the best-performing animals have higher-than-average expression of several components of 
the translational machinery and that the opposite is true for the animals with poor performance.
GSEA also indicated that the high expression of glutamate receptors correlated with poor performance 
in old age.  The average gene expression levels for the genes in the glutamate signaling pathway were 
calculated for the 3 animals with the best and worst performance on the water maze task. The ratio of 
these gene expression levels to mean expression of these genes in the entire group is represented in (Fig 
3.1.6C). The 'poor learners' show high expression of several components of the pathways and the 'good 
Results
67





















































































3.1.6.1 Diagram showing components of the murine ribosome
Average expression in the 3 highest performing mice (A) and the 3 lowest performing mice (B) Green represents expression below mean and red represents 
expression above mean. Color intensity depends on the ratio of expression levels of the gene to mean expression levels.Genes with prefix L code for proteins in 
the large subunit and those with prefix S code for proteins in the small subunit. Figure generated using Ingenuity IPA software. Figure 3.1.6.1 Diagram showing components of the murine ribosome
Average expression in the 3 highest performing mice (A) and the 3 lowest performing mice (B) Green 
represents expression below mean and red represents expression above mean. Color intensity depends on 
the ratio of expression levels of the gene to mean expression levels.Genes with prefix L code for proteins 

































































































Figure 3.1.6.2 Translation initiation pathway diagram
Average expression in the 3 highest performing mice (A) and the 3 lowest performing mice (B) Green 
represents expression below mean and red represents expression above mean. Color intensity depends 
on the ratio of expression levels of the gene to mean expression levels. Symbols containing a mixture of 
green and red indicate that some isoforms of this protein were overexpressed and others underexpressed. 
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Figure 3.1.6.3 Glutamate signaling pathway diagram
A: Average glutamate receptor expression in the 3 highest performing mice B: Average glutamate receptor 
expression in the 3 worst performing mice. Green represents expression below mean and red represents 
expression above mean. Color intensity depends on the ratio of expression levels of the gene to mean 
expression levels.  Symbols containing a mixture of green and red indicate that some isoforms of this 
protein were overexpressed and others underexpressed. Figure generated using Ingenuity IPA software.
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3.1.7 MicroRNA expression in aging mice
The expression of microRNAs in the same group of 16-month-old mice was analyzed in a manner similar 
to the mRNA. Pearson's correlations between the expression of each microRNA and the water maze probe 
test were calculated for every individual mouse. The expression levels of 16 microRNAs had a significant 
positive correlation with probe test performance and 11 had a significant negative correlation with probe 
test performance (Fig3.1.7 B and C). 
To study the biological significance of these microRNA lists, the web-based 'Tool for analysis of microRNAs' 
(TAM) was used. TAM uses a relatively stringent algorithm to scan lists of microRNAs for over-representation 
of categories of biological such as families, clusters, biological pathways or using prior knowledge [221]. 
This method was developed as an alternative to the widely used alternative target-prediction based analyses 
of microRNA lists, which depend on sequence-motif based target prediction and result in a large number of 
false positives. Submitting the lists of microRNAs significantly correlated with probe test performance to the 
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Figure 3.1.7 MicroRNA expression in aging mice
A: Time spent in target quadrant by 16-month-old mice(n =22), plotted individually and sorted from worst 
performace to best performance. Heat maps showing the scaled, normalized expression values of the 20 
microRNAs most significantly correlated positively (B) and negatively (C) with performance on the probe test. 
Color scale represent levels of expression, with blue representing highest expression and red representing 
the lowest expression. D: Examples of correlations between performance and microRNA expression for the 
microRNAs mmu-miR-3070b-3p, -3097-3p, and -135a-2*  which correlate positively with performance, and  miR-
598, -679-5p and -192 whose expression correlates negatively with performance. The microRNA expression 
levels are plotted as normalied read counts on the vertical axis versus the probe test performance (percent time 
spent in target quadrant) on the horizontal axis.  Deming regression lines are indicated and each solid circle 
represents an individual animal, (n = 22).
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3.2 Alzheimer's disease
3.2.1 Gene and microRNA expression in the APP-PS1 mouse model
To compare the mRNA and microRNA profile seen in age-associated memory impairment with that 
associated with amyloid pathology in AD, we used the double transgenic mouse strain APP-PS1. This 
strain was engineered to overexpress 2 AD-associated mutations in neurons and has been used widely as 
a mouse model for cerebral amyloidosis. 
The APP-PS1 mice show neocortical amyloid deposition as early as 6–8 weeks of age. Hippocampal amyloid 
plaques are observed in the dentate gyrus at 2–3 months of age and in the CA1 at 4–5 months of age. The 
mice show no abnormalities in motor abilities or exploratory behavior but clear deficits in reversal learning 
and spatial memory are seen by 8 months of age [222, 223].  However, like the other existing amyloid-based 
mouse models, the APP-PS1 mice show neither the tau pathology nor the frank neurodegeneration seen in 
human AD [222].  Nevertheless, they have been widely studied in the context of neurodegenerative disease 
and several aspects of their neuropathology associated have been reported.  The APP-PS1 mice show 
decreased neurogenesis and disrupted functioning of hippocampal neuroprogenitor cells [224], decreases 
in learning-induced upregulation of gene expression [225], impaired LTP in the CA1 region, and impaired 
microglial motility and phagocytosis behavior. This strain has also been used to test therapies for amyloid-
associated pathology such as HDAC inhibitors [223], microRNAs [226], plaque-targeted T cells [227], NMDA 
receptor antagonists [228],  ApoE reduction [229, 230] and exposure to enriched environments [230].
 Thus the molecular pathology and electrophysiology of these mice has been characterized, but little is 
known about the hippocampal transcriptomic response to overexpression of these human AD proteins. 
Since the plaque pathology and cognitive deficits are well established by 8 months of age, we chose 
to compare that age to an earlier time point (4 months) to capture the early detrimental effects of the 
overexpression. The hippocampal transcriptomic profile in groups of APP-PS1 mice at both ages was 
studied by by RNA and small RNA sequencing and compared with that of their wild-type littermates.  In the 
4-month-old group 34 transcripts were differentially expressed in comparison to wild type mice,  of which 
22 were upregulated and 12 downregulated in the APPPS1 mice. The 8-month-old group showed more 
evidence of transcriptional changes, with 299 genes down regulated and 185 genes upregulated over 
controls. 
The results of miRNA profiling were less informative — when an unsupervised clustering approach was 
used to study the intra- and inter-group similarity in microRNA expression, the transgenic mice did not form 
a distinct cluster (Fig 3.2.1B). After correcting p values for multiple testing, 16 out of the 855 expressed 
microRNAs showed a significant difference between groups. At 4 months of age, the microRNAs mmu-miR-
3096b, -409, -541, -221*, 30c-2* and -370 * were lower in the APP mice while mmu-miR-335, -490, -700*, 
-451, -142, -495, -136, -381*, -879* and -26a-2* were significantly raised in the APP mice (Fig 3.2.1C).  At 
8 months of age,  the only microRNA differentially expressed between groups was mmu-miR-122. There 


















































































































































Figure 3.2.1 microRNA expression in the APP-PS1 mouse model
A: Scheme showing microRNA differential expression in APP and WT mice at the ages of  4 and 8 months. 
B: Unsupervised clustering of samples by microRNA expression values. C: Differentially expressed 
microRNAs in APP mice at 4 months and 8 months of age (FDR = False discovery rate, FDR , 0.05)
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3.2.2 RNA isolation from human cerebrospinal fluid
Given recent reports that cells secrete RNA-containing vesicles into extracellular fluid under physiological 
conditions (see section 1.2.5), we tested various fractions of human cerebrospinal fluid for RNA (Fig 3.2.2A). 
CSF from two subjects was used to identify the fraction with the highest RNA yield. RNA was isolated from 
the large extracellular vesicle (EV), exosome, and exosome-free CSF fractions derived from 2 ml of CSF 
from each patient and the size profile and the amount of RNA isolated was studied on a bioanalyzer. For 
both samples, the exosome fraction yielded the maximum total RNA (Fig 3.2.2B). The RNA yield differed 
between subjects, but the proportional distribution of RNA in the various fractions CSF remained constant. 
Next-generation sequencing was carried out on the total RNA (derived from 2 ml volume) from each fraction. 
As predicted by the bioanalyzer output, the exosome fraction had the most RNA reads. The exosomes also 
had the highest proportion of reads mapping to microRNA (Fig 3.2.2C). Further the number of microRNAs 
that could be detected, and the absolute number of microRNA reads was also highest in the exosome 
fraction (Fig 3.2.2D). 
To confirm the results of next-generation sequencing qPCR for 10 miRNAs was performed on the exosome 
and exosome-free fractions. Of the 10 microRNAs tested, all were found in the exosome fraction, one was 
also found in the exosome-free CSF (Fig 3.2.2E). Notably, there were no microRNAs in exosome-free CSF 
that could not be detected in exosomes.
E
Figure 3.2.2 RNA isolation from human cerebrospinal fluid (Facing page)
 A: Scheme showing CSF fractions and their isolation,  B:  Bioanalyzer picochip profiles, with size 
in nucleotides on the horizontal axis and quantity in fluorescent units (FU) on the vertical axis, of CSF 
exosomal RNA  from a 71-year-old male subject without alzheimer's disease, C: Pie charts showing the 
RNA composition of each fraction, D: Graphs showing total RNA reads, total microRNA reads and number 
of microRNAs detected in each fraction. E: qPCR to detect 10 miRNAs in exosome and exosome-free 











3.2.3 The RNA contents of the CSF exosome
For a better understanding of the exosomal RNA contents, we compared RNA from CSF exosomes to RNA 
from human plasma exosomes and from exosomes derived from primary hippocampal cell culture by NGS 
(Fig 3.2.3.1 and 3.2.3.2)
3.2.3.1 Size profiles
Comparing the size profile of CSF exosomal RNA to that of plasma exosomes and exosomes isolated from 
mouse primary cortical neuron cultures revealed that the profile was quite similar, with a peak in the small 
RNA region (20-200 nt), and very little evidence of larger RNA species (Fig 3.2.3.1A, B and C). In contrast, 
the size profile of cellular RNA from primary cortical neurons or mouse hippocampus (Fig 3.2.3.1 D and E) 
shows prominent large RNA peaks corresponding to the 18S and 28S ribosomal subunits. 
To confirm that our exosomal RNA isolation procedure yielded pure RNA with no DNA contamination, we 
studied the bioanalyzer profile of RNA isolated from exosomes belonging to mouse primary cortical neuron 
cultures before and after treatment with RNase and DNase.  As seen in (Fig 3.2.3.1 F-I) DNase treatment 
had no effect on the profile while RNase treatment completely digested the exosomal nucleic acid content. 
3.2.3.2 RNA contents of CSF exosomes
To study the content of CSF exosomal RNA in further detail and to facilitate the identification of the various 
RNA species contained therein, we divided the RNA into 2 fractions and sequenced them separately. 
The size fractions corresponding to 0‒40 nt (expected to be rich in miRNAs) (Fig 3.2.3.3)  and 40‒200 nt 
(containing the second peak) were sequenced (Fig 3.2.3.2) in RNA from 4 CSF exosome samples. 
As expected, the 2 fractions were very different in their RNA contents (Fig 3.2.3.2B-E). The 0‒40 nt fraction 
contained about 9% miRNA, a small fraction of mRNA, and about half the reads mapped to other non-
coding RNA. A large proportion of the reads from this fraction could not be mapped with confidence to the 
genome. By contrast, the 40-200 nt fraction consisted entirely of reads which could be mapped to non-
coding RNAs other than miRNA.
The non-coding RNA in the exosomes is described below and the microRNA in Section 3.2.3.3. 
The larger region (40‒200nt) was found to contain about 2 million non-coding RNA reads, mapping to over 
4500 non-coding RNAs. In comparison, the 2‒40 nt region contained about 200000 non-coding RNA reads 
(Fig 3.2.3.2 C). The large majority of the larger non-coding RNAs, including the most highly expressed ones 
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Figure 3.2.3.1 Exosomal RNA bioanalyzer profile
Bioanalyzer RNA picochip profiles, with size in nucleotides (nt) on the horizontal axis and quantity in 
fluorescent units (FU) on the vertical axis A: RNA from human CSF exosomes, B: RNA from human 
plasma exosomes, C: RNA from exosomes in the culture medium from primary cortical neurons, D: RNA 
from primary cortical neurons in culture, E: RNA from whole mouse hippocampal tissue F: Untreated 
exosomal RNA, G: Exosomal RNA treated with DNase, H: Exosomal RNA treated with RNase and I: The 
first 3 profiles overlaid.
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Figure 3.2.3.2 Exosomal RNA content
A: Average number of reads per million that map to microRNA  (n = 4), B: Average number of reads per 
million that map to microRNA  (n = 4), C: Average number of reads per million that map to other (non-
miRNA) non-coding RNA (n = 4, logarithmic scale), D: RNA distribution within fraction 1(20-40nt) and 
fraction 2(40-200nt) of  CSF exosomal RNA, E: 25 most highly expressed non-coding RNAs from NGS of 













































































Figure 3.2.3.3 Exosomal microRNA content (Facing page)
A: Approximate size of the RNA fraction used for sequencing (0-40nt)  B: Pie charts representing the 
relative proportion of microRNA,  small non-coding RNA and other coding or unknown RNA  in CSF 
exosomes, plasma exosomes and exosomes from primary hippocampal cultured neurons. Both CSF 
and plasma exosomes were derived from the same patient, a 64-year-old male with Alzheimer's disease. 
C: Average number of microRNAs detected in CSF exosomes, plasma exosomes and exosomes from 
primary hippocampal cultured neurons. between samples, with one sample on the horizontal axis 
Results
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Fig 3.2.3.3 D. Scatterplots showing correlations in miRNA expression versus 2 other randomly selected 
samples on the vertical axis. Each dot represents an individual miRNA and R stands for Pearson's 
correlation coefficient. For exosomes from primary hippocampal cell, the 3 exosome samples were 
collected from independent culture dishes. Plasma and CSF are from 3 different subjects. E: The top 30 
microRNAs in  CSF exosomes, plasma exosomes and exosomes from primary hippocampal cultured 
neurons.
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3.2.3.3 Small RNA and microRNA 
The majority of small RNA is the CSF exosomes is non-microRNA small non-coding RNA. A large number 
of transcripts also derive from coding regions. MicroRNA forms not more than 15% of total exosomal RNA 
in exosomes from either CSF, plasma or primary neuronal culture (Fig 3.2.3.3B). Despite the relatively 
low overall proportion of microRNAs in exosomal RNA, the number of microRNAs that can be detected is 
large. We were able to detect at least 150‒250 microRNAs in each sample of CSF exosomes and 100‒200 
in each sample of plasma exosomes. In total, 412 different microRNAs could be reliably detected in CSF 
exosomes across all samples (> 10 reads). In exosomes from primary hippocampal neurons, although the 
proportion of microRNA appears to be even lower, about 500 microRNAs could be detected (Fig3.2.3.3C). 
The microRNA profile obtained by NGS of exosomes appears to be highly technically reproducible. After 
applying a square-root transform to control for undue influence by highly expressed microRNAs, correlations 
in microRNA expression levels between samples were measured. In exosomes from primary hippocampal 
cultures, the inter-sample correlations were above 90%. The correlations in CSF and plasma were from 
70-80%. Considering that these comparisons were performed in unrelated individuals with varying health 
status, including both patients with AD and healthy controls, these results indicate a high degree of general 
similarity in the exosomal RNA expression patterns. The microRNA expression pattern, however, differs 
widely depending on the biological fluid used as a source of exosomes. There are no obvious similarities 
in microRNA expression levels between exosomes from CSF, plasma and primary neurons (Fig 3.2.3.3E).
3.2.4 Exosomal RNA versus cellular RNA
After verifying that the small amounts of RNA isolated from CSF exosomes can be studied by NGS, the 
next step was to study the relationship between exosomal RNA and RNA in the cell that secretes them. To 
enable a direct comparison RNA was isolated from primary hippocampal neurons in cell culture at 14 days 
in vitro and from the exosomes isolated from the growth medium of these cells. As shown in Fig 3.2.3.1, 
exosomal RNA is almost exclusively in the 20‒200nt size range, while cellular RNA contains larger species, 
with the 18S and 28S subunits of ribosomal RNA forming prominent peaks. NGS of exosomal and cellular 
small RNA revealed that certain microRNAs appear to be selectively exported into exosomes, and others 
selectively depleted (up to 35-fold in both directions) (Fig 3.2.3.4A). Further, not all cellular microRNAs can 
be detected in exosomes, and not all exosomal microRNAs can be detected in cells (Fig 3.2.3.4B).
To determine if exosomal RNA changes after perturbation of the cells in vitro, exosomes isolated healthy 
cultures (control) were compared with those isolated from cultures treated with amyloid-beta (Fig 3.2.3.4D). 
NGS revealed that cells and exosomes both contain a relatively small proportion of microRNA, and 
exosomes are not enriched in microRNA compared to cells, but rather contain a slightly lower proportion of 
miRNA than the corresponding size fraction in the cell. After treatment with A-beta, a shift in distribution of 
RNA was observed. In primary neurons, there was an increase in the proportion of other small non-coding 
RNA (non-miRNA) with a corresponding decrease in mRNA and long-non-coding RNA. These changes 
were reversed in exosomes, with a remarkable increase in proportion of reads mapped to mRNA and long-
non-coding RNA and a decrease in small non-coding RNA. The proportion of microRNA remained relatively 
unchanged after treatment with A-beta. 
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A-beta treatment causes changes in microRNA expression pattern of both cells and exosomes, but exosomal 
changes do not parallel cellular changes. There is little overlap between the microRNAs differentially 
expressed after A-beta treatment in primary neurons and exosomes isolated from those neurons.  However 
the changes in both cells and exosomes are clear enough to be detected by an unsupervised clustering 
algorithm. Exosomes from A-beta-treated cells and exosomes from untreated cells form distinct clusters 
(Fig 3.2.3.4 F).
A
Figure 3.2.4 Exosomal RNA versus cellular RNA
A: Average ratio of exosomal level to cellular level for all microRNAs expressed in both exosomes and 
cells and miRNAs with the highest and lowest exosome-to-cell expression ratio (n = 3 per group, error 







































Figure 3.2.4 Exosomal RNA versus cellular RNA
C: MTT assay to assess viability of treated neurons after treatment with A-beta 42 oligomers, vehicle 
control (control1) and A-beta 40 monomers (control2) D: Pie charts showing proportion of reads mapping 
to RNA categories (single representative images, original experiment was performed in 3 replicates). 
E: microRNAs differentially expressed in neurons and exosomes after A-beta treatment (n =3 per 
group,unadjusted p value < 0.05) F: Unsupervised clustering of A-beta treated exosomes and cells, 
based on all expresed microRNAs
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3.2.5 Sequencing RNA from small volumes of CSF
If RNA isolated from cerebrospinal fluid exosomes is to be used for studying brain disease on a larger 
scale, the procedure must be feasible from small amounts of starting material. CSF stored in biobanks 
for clinical studies is typically available in volumes of 1‒2ml. Using the RNA isolation protocol described 
above, the amount of exosomal RNA isolated from 1 ml of CSF was on the order 3-4 nanograms, with 
considerable variation from sample to sample (Fig 3.2.3.5A). In order to ensure that RNA sequencing could 
be reproducibly performed from these small starting amounts, we performed serial dilutions from a pool of 
CSF exosomal RNA, sequenced them and compared the results. As seen in Fig 3.2.3.5B, the sequencing 
protocol is highly reproducible for starting amounts as low as 0.5 ng of RNA.  Further,  these small starting 
volumes were used to check if CSF samples from 2 different subjects could be separated. Interestingly, 
as little as 0.25 ng of RNA from CSF exosomes was enough to distinguish between 2 subjects by an 
unsupervised clustering algorithm (Fig 3.2.3.5C).
3.2.6 CSF RNA in Alzheimer's disease
The final step was to compare CSF exosomal RNA between AD patients (n=18) and control subjects (n=20) 
by next generation sequencing. 
3.2.6.1 Differential expression and unsupervised clustering
After studying the CSF exosomal RNA content by next generation sequencing, the next step was to test 
if this exosomal RNA could be of use in further understanding the pathophysiology of AD. CSF exosomal 
RNA from 18 AD patients and 20 controls was sequenced and differential expression of microRNAs was 
analyzed (Fig 3.2.6.1B). After adjusting the p value by the Benjamini-Hochberg procedure for multiple 
testing, a list of 7 microRNAs (hsa-miR-192-5p, -486-5p, -598, -122-5p, -25-3p, -375, and -3591-3p ) were 
significantly lower in the CSF exosomes of patients with AD. Of a total of 412 expressed miRNAs, 41 
microRNAs were found to be differentially expressed with a significance level of less than 0.05 (p value 
unadjusted for multiple testing) 12 were higher in AD patients than in controls and 19 were lower. 
The microRNA expression was then used to classify the samples using an unsupervised clustering 
algorithm. The samples clustered into 2 large groups, with one cluster having predominantly AD patients 
and the other cluster predominantly control subjects, but perfect separation could not be achieved (Fig 
3.2.6.1 A). Notably, several other potential confounding factors such as age, gender or medication intake 
also did not seem to have an effect on sample clustering, but the medical facility of origin of the samples 
(center where the CSF was withdrawn and stored before exosome isolation) did appear to influence the 
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Figure 3.2.5 Sequencing RNA from small volumes of CSF
A: Average RNA amount in nanograms isolated from exosomes from 2 ml CSF, (error bars represent SEM) 
B: Correlations in miRNA expression between serial dilutions (5, 1, 0.5 and 0.25 ng of CSF exosomal RNA) 
C: Inter- and intra-subject correlations from varying amount of CSF exosomal RNA. Color and size of the 





Figure 3.2.6.1 Differential expression and unsupervised clustering of CSF exosomal RNA from AD 
patients
A : Heatmap and dendrogram showing unsupervised hierarchical clustering of patients by CSF exosome 
microRNA expression profile . Each vertical row correspond s to a single patient and the annotations at the 
bottom of the plot represent patient characteristics. The horizontal rows represent individual microRNAs 
and the color values represent microRNA expression levels (red signifies  expression higher mean and 
green lower than mean) Med = medication, AcheI = Acetyl cholinesterase inhibitor, Diag = diagnosis B: 
Differentially expressed microRNAs between AD patients (n = 18) and controls (n = 20). P values after 
adjusting for multiple testing are 4.13E-05, 5.53E-05, 0.000964, 0.019274, 0.024969 and 0.027931 
respectively. Error bars represent standard error of mean.
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3.2.6.2 Machine learning approach to predict AD
The Random Forest machine learning algorithm was used to check if a combination of microRNAs could be 
selected that would allow a prediction of diagnosis based entirely on exosomal RNA. The set of 38 samples 
was divided randomly into a 'training set' of 28 (13 AD and 15 controls) and a 'testing set' of 10 (5 AD and 
5 controls). Iterations of variable ranking by importance, estimation of accuracy by cross-validation and 
optimization of the number of microRNAs selected for the final model were performed on the training set. 
An internal accuracy rate of above 70% (out-of-the-bag error rate of 28 %), estimated by cross validation 
within the training set was achieved with a set of 25 microRNAs. As seen in Fig (3.2.6.2C) the lowest error 
rate in these data is obtained by using about 25 features. When the microRNAs were ranked by relative 
contribution to the prediction, the top microRNA, hsa-miR-34c appeared to contribute about 2-fold more 
than the other microRNAs (Figure 3.2.6.2B). Interestingly, the predictive microRNAs are not exactly the 
same as the most highly differentially expressed, although the 2 lists overlap. Finally, the model based on 
25 selected microRNAs was tested on the testing set and a similar accuracy rate of 70% was achieved (Fig 
3.2.6.2D). 
Since the small fraction of the exosomal RNA (20-40nt) contains more than 3000 other non-coding RNAs, 
the non-coding RNA data were also used to attempt a prediction. Training and testing were performed in 
exactly the same manner as in Fig 3.2.6.2A for the AD patients and controls using a dataset consisting of 
other non-coding RNAs. Again, the lowest error rate by internal cross-validation within the training set was 
achieved at about 25 features (Fig 3.2.6.2F).  When tested using the testing set, a higher accuracy rate of 
80% was achieved (Fig 3.2.6.2G). 
Finally, the 25 most predictive microRNAs and other non-coding RNA lists were combined to generate a 
combined dataset of 50 features, which was then trained and tested in a similar manner. The combination 
achieved an accuracy rate of 0.82 (2 errors out of 11 predictions) (Fig 3.2.6.2H).
For additional notes on the Random Forest algorithm and variable importance ranking, see Appendix 1
Figure 3.2.6.2 Machine learning approach to predict AD (Facing page)
Legend : A. Scheme used for training and testing the Random Forest algorithm, B; The top 10 microRNAs 
selected by the random forest algorithm as predictors of disease status in decreasing order of importance.
Horizontal axis is represents decrease in Gini index (See appendix 2) C. Estimation of optimal number 
of microRNAs to be used for the prediction algorithm. On the horizontal axis are the number of features 
or microRNAs, and the vertical axis denotes the error rate estimated by cross-validation within the 
training set, D: Result of testing of the 25-microRNA model on the testing set, error rate = 3 out of 10, E: 
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Figure 3.2.6.2 Machine learning approach to predict AD
F: The top 10 other non-coding RNAs selected by the random forest algorithm as predictors of disease 
status in decreasing order of importance, G:  Estimation of optimal number of other non-coding RNAs 
to be used for the prediction algorithm. On the horizontal axis are the number of features or other non-
coding RNAs, and the vertical axis denotes the error rate estimated by cross-validation within the training 
set. H:  Result of testing of the 25-other-non-coding-RNA model on the testing set, error rate = 2 out of 10, 
I: Result of testing the combined (MicroRNA and other non-coding RNA) 50-feature model on the testing 
set, error rate = 2 out of 11. J: Result of using an independent machine learning algorithm (Support vector 
machines) to test the combined (MicroRNA and other non-coding RNA) 50-feature model on the testing 








4.1 Gene expression changes in age-associated memory impairment
4.1.1 Heterogeneity in aging
The proportion of elderly people in the world population has risen considerably in the past few decades, and 
continues to increase [231]. This demographic trend was initially particularly pronounced in the Western 
world, but is starting to be seen as a worldwide phenomenon that includes the large population groups in 
the developing countries [232]. Aging not only increases susceptibility to cardiovascular, orthopedic, and 
malignant and other diseases, but is also the most important risk factor for diseases of the cognitive system 
such as Alzheimer's disease. This means that it is more crucial than ever to understand the biological 
mechanisms of aging, and to investigate ways to prevent and treat age-associated diseases.
 
Although aging affects populations as a whole, there is a marked variability in the extent to which individuals 
are susceptible to its detrimental effects. This variability can be seen between different species, between 
different individuals within a species and between different tissues or cell types within the organism [233]. 
Inter-individual variation in rates of aging can be attributed to a complex mixture of factors. From twin 
and family studies, it is clear that genetics plays an important role in determining individual susceptibility 
to age-related changes, as does maternally inherited mitochondrial DNA [233]. At the same time lifestyle 
factors, diet, exercise, and the cumulative effects of exposure to various other environmental stimuli also 
drive age-related changes, and the degree of the respective contributions is hard to quantify. Studying 
these environmental and epigenetic factors is especially important when trying to find mechanisms that are 
amenable to therapeutic or preventive intervention.
The process of aging affects multiple organ-systems in the human body. Some of these age-related changes 
like the graying of hair are relatively benign, while others have more serious consequences. One of the age-
related changes that contributes the most to functional decline in the elderly is the loss of cognitive function. 
It is well known that the age-related impairment specifically affects certain domains of cognition, such as 
the ability to learn and recall new information [234-236]. Studies in aging people show that learning and 
memory abilities of a group of aged individuals lie across a wide spectrum with some individuals retaining 
high performance in old age, while others decline at varying rates [237].
These observations have been reproduced in rodents, largely in rats, where it has been shown that aging is 
associated with increased variability on a number of tasks [238-240]. From the results in Fig 3.1.1 it is clear 
that a large inter-individual variability in age-associated memory decline can be seen in wild-type mice at 
the age of 16 months. Since the lifespan of a mouse is up to 24 months, the 16-month age corresponds to 
late middle age. The reasoning behind the choice of this age-group was that intra-group variability would 
peak at late-middle-age, and the group of mice would be likely to contain individuals with preserved learning 
and memory as well as those who showed early decline. By contrast, in a group of mice at an older age 
most of the animals would be expected to show impairment. In support of this, post-mortem analysis of the 
human frontal cortex has shown that the largest heterogeneity in gene expression occurs in the middle-to-
late ages, with relatively less intra-group variability in the young, the middle-aged and the oldest patients 
[241]. As seen from Fig 3.1.2 the increased variability seen on the water maze task is not replicated in the 
fear conditioning and novel object recognition tasks. Since these tasks require different sets of cognitive 
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skills and involve different brain regions (See Section 1.1.6 and 4.1.3) it is possible that they decline at 
different rates, and perhaps a different age group would show a wider variability in performance on these 
tasks.
Previous studies of the transcriptional changes in aging and age-related memory impairment have largely 
involved testing between 2 or more groups of animals at different ages [242-244]. Between-groups 
experimental designs are able to to identify the large groups of genes that are differentially expressed 
between young and old individuals. However they can not distinguish between benign age-associated 
changes and those that are associated specifically with the impairment of the function under study. The 
advantage of studying the spectrum of cognitive abilities using a single-group design is that the intra-
group variability provides a means to separate the mechanisms associated with functional impairment from 
the background age-related changes. Additionally, it would perhaps allow a clearer demarcation between 
age-related changes that cause detrimental function and those that are part of a beneficial compensatory 
response. This provides a system for studying the underlying molecular changes that signal those subtle, 
cumulative insults that are associated with memory decline in aging.
4.1.2 Distinguishing aging individuals with age-associated memory impairment 
Drawing inferences about the cognitive consequences of age-related molecular changes is not a 
straightforward process. As the aging process is associated with altered functioning, deterioration and 
potentially compensatory responses in many organ systems and cellular and molecular processes, there 
is a lot of room for confounding factors when making conclusions about the mechanisms driving age-
related cognitive decline. Some examples of these factors are the deterioration of the musculoskeletal and 
visual systems that could influence the interpretation of mouse behavior tests, and histopathological and 
molecular alterations that are associated with senescence but unrelated to cognition.
Although Fig 3.1.1 demonstrates increased variability in aged mice on the water maze task, it is not clear 
from these results whether the differences in performance are consistent between testing days. The 
water maze paradigm was ideal for demonstrating this, since it consists of several consecutive days of 
training and testing. A correlation analysis was therefore necessary in order to check whether the 'poor' 
or 'good' performance of the mice is more than an occasional phenomenon and to allow tracing of 
individual performance over time. The correlation tests in Fig 3.1.3 show that for all age groups, the level 
of performance remains relatively consistent over days. This analysis is also useful to distinguish good 
learners from poor learners for subsequent molecular analysis. Moreover, these results also distinguish 
inter-individual variability from intra-individual variability of inter-day fluctuations in performance. In our 
study, individuals were monitored simply be keeping them single housed for the duration of the experiments. 
A similar recently published study studying inter-individual variability in mice employed group housed mice 
with radio-frequency identification tags and antennae placed in the cage [245]. This study focused on 
exploratory behavior rather than learning or memory.
The spatial memory involved in the Morris water maze task is known to be primarily hippocampus-dependent 
[246] at the time points tested in this experiment. The fear conditioning task is known to involve both the 
amygdala and the hippocampus. While the amygdala is critical to the fear response [247], the contextual 
fear memory also involves the hippocampus [248].
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In mice the recognition of novel objects depends on the rhinal cortex [249], but the novel object recognition 
task is a complex task that likely involves several other brain regions that encode and retrieve memory of 
the familiar object. Within the hippocampus, place cells are known to encode specific locations [250], and 
neuronal activity patterns that encode time and distance traveled by an animal [251]. The learning- and 
memory-associated activities involved in each of the tasks tested here require a combination of several 
different activity patterns. 
Thus the demonstration that individual performance varies for different types of memory is not unexpected, 
and is further evidence for independent mechanisms in these types of learning.
4.1.3 Comparison with previous rodent studies on age-associated memory impairment
In order to dissect out the general mechanisms that accompany aging from those which specifically relate 
to age-related cognitive impairment, a series of studies was performed on aged rats, which show intra-
group variability in the ability to learn spatial tasks [252]. In contrast to the work described in this thesis, 
where molecular correlations were drawn across a spectrum of behavior performance, the aged rats were 
divided into two groups –  learning-impaired and learning-unimpaired [253-255]. By semi-quantititative 
immunohistochemistry, it was shown that the expression of the AMPA receptor subunit GluR1 and PSD-95 
were increased in those rats that showed impairment with aging [255].
  
Studies in rats also show that animals that age successfully or retain their cognitive capabilities as they age 
do so by switching to an alternative mode of synaptic plasticity. While young animals use NMDA receptor 
dependent LTP and LTD, successful preservation of plasticity in aged animals is associated with a switch 
to NMDA-receptor- independent LTP and mGluR-dependent LTD [256].
The relationship between adult hippocampal neurogenesis and spatial learning in aged rats has also been 
investigated extensively, with somewhat contradictory results. Gene expression data from the dentate 
gyrus of these rats suggest that a decrease in expression of neurogenesis-related genes occurs uniformly 
with aging, and does not relate with learning impairment [257]. Studies of BrdU-positive cells (a marker 
for cell proliferation) in the hippocampus of aged rats showed that high BrdU-positivity in the hippocampal 
granule cell layer correlated with worse performance [258], or showed no correlation with performance 
[253]. Other studies with similar methodologies have shown that aged-unimpaired rats show higher levels 
of cell proliferation than aged-impaired rats [259].An isolated report suggesting impaired differentiation 
of newborn granule cells correlates with impaired learning [260] came under strong scrutiny, when a 
reevaluation of the correlations between the behavioral and immunofluorescence data showed the opposite 
to be true [261-263].
Interestingly, there are reports that markers of immature neurons are enhanced in patients with AD [264] 
and there is increased neurogenesis in the dentate gyrus and subventricular zone of a transgenic AD 
mouse model [265]. 
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4.1.4 Ribosomes, translation and RNA-binding proteins in learning and memory
The overlapping sets of genes coding for ribosomal proteins, RNA-binding proteins and the translational 
machinery show a correlation with memory performance in old age. Aging mice expressing high levels of 
these genes in the hippocampus perform better than average on the water maze task. From Fig 3.1.6.1 and 
3.1.6.2 it is clear that the entire translation initiation pathway is expressed at high levels in these animals. 
The control of plasticity at the level of translation is a well known phenomenon and many components of 
these pathways have been studied in detail with respect to learning and memory
4.1.4.1 RNA-binding proteins, RNA transport and activity-dependent local translation
RNA-binding proteins (RBPs) are a group of proteins that form complexes with RNA in the cellular 
nucleus or cytoplasm. The nuclear RBPs mostly form complexes with pre-mRNA, called heterogeneous 
ribonucleoprotein particles but the cytoplasmic RBPs are more diverse and are known to carry out a variety 
of functions. Some of the functions that have been ascribed to RBPs include export of RNA from the nucleus 
into the cytoplasm, regulation of splicing and alternative splicing, RNA editing, and polyadenylation of mRNA 
transcripts, and constraining their translation [266]. Thus they are key regulators of postranscriptional 
processing of RNA. One particularly interesting function of RBPs with respect to neurons is their role 
controlling RNA localization, particularly in regulating mRNA transport to the site of local translation [266]. 
The RNA-binding protein FMR1, or the fragile X mental retardation protein 1 gene was found in the gene 
set that correlated with good performance. FMR protein (FMRP) plays a role in synaptic plasticity and 
activity-dependent translation at the synapse and is key for mGluR-dependent LTD. FMRP is involved 
in activity-dependent mRNA transport in neurons [267-269]. This protein has also been shown to be a 
translation inhibitor, repressing activity-dependent translation [270], and to inhibit the translation of specific 
mRNAs at the synapse [271]. Further, there is strong evidence for a relationship between FMR1 and 
glutamate receptors. The translation of Fmr1 and the localization of the mRNA to dendrites is regulated by 
activation of group 1 metabotropic glutamate receptors (mGluRs) [269].  At the synapse, mGluR activation 
however, leads to degradation of the FMR protein, [272]. In mice where activity-dependent FMR translation 
is impaired, mGluR-mediated long-term depression (LTD) is enhanced. Stau2, and Hnrnpa2b1 are other 
genes on the list that are also known to be closely associated with the RNA granules that are transported 
to the dendrites as a part of local protein synthesis [273, 274].
 4.1.4.2 Insulin signaling, mTOR and translational regulation
Eukaryotic Initiation Factor 2 (eIF2) and polyA binding protein, twp of the genes whose expression correlated 
most highly with behavior performance in old age are key players in the initiation of mRNA translation. As 
shown in Fig 3.1.6.2 eIF2 binds guanidine triphosphate and the initial methionine-tRNA before forming a 
complex with the other translation initiation factors eIF1, eIF2A and eIF3. The polyA binding protein (PAPB), 
another important component of the translational machinery also appears to be regulated in the same 
direction as the eIFs.
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Many of the genes coding for ribosomal proteins, as also the translation initiation factors are regulated by 
mTOR. There is a large body of evidence pointing to the involvement of the mammalian target of rapamycin 
(mTOR) in neuronal translation regulation [275]. mTOR couples the activity of neuronal surface receptors 
to the protein synthesis required for synaptic plasticity. The mTOR inhibitor rapamycin acts by disrupting 
the mTOR protein complex (MTORc) [276]. High levels of mTORc1 repress the eIF4E-binding proteins 
(4E-BPs). Rapamycin-sensitive mTOR signaling is essential to protein synthesis-dependent synaptic 
plasticity [277]. Moreover, mTOR signaling is also essential to mGLuR-dependent neuronal LTD (distinct 
from N-methyl-D-aspartate receptor (NMDAR)-dependent LTD) [278]. 
In a rat model of accelerated aging, the mTOR inhibitor rapamycin allayed cognitive deficits and prevented 
the onset of structural brain abnormalities associated with senescence [279]. Inhibition of the mTOR complex 
by rapamycin was shown to increase lifespan in both genders and in wild type mice with different genetic 
backgrounds [280]. In human studies, there is preliminary evidence that treatment with mTOR inhibitors 
could lead to improvement in memory and concentration, among other psychiatric symptoms [281]. 
Although it has been established that synaptic activity causes mTOR to interact with and regulates translation 
initiation factors and S6K, it does not universally upregulate translation at the activated synapse. Increased 
mTOR activity specifically downregulates the expression of proteins such as IRS2 (Insulin receptor substrate 
2) and dendritic translation of voltage gated potassium channel 1.1(Kv1.1) [282].  Interestingly, comparing 
the expression of genes within the translation initiation pathway between good learners and poor learners 
(Fig 3.1.6.2) suggests that the expression of insulin and components in the insulin-signaling pathways may 
be important events in the process. 
4.1.5 Glutamate receptors, excitotoxicity and memory impairment
From the results of the gene set enrichment analysis and the more detailed gene-level analysis in sections 
3.1.5 and 3.1.6 it appears that high hippocampal expression of components of the glutamate signaling 
pathway correlates with poor memory performance in old age. These components include a number of 
postsynaptic glutamate receptor subunits, but overexpression at the gene expression level can not be 
directly interpreted as heightened glutamatergic signaling at the synapse. Moreover while these changes 
in glutamate receptor subunit expression certainly indicate a connection between glutamate signaling at 
the synapse and the maintenance of memory in old age, it is not clear whether high levels of glutamate 
receptors are a cause or a consequence of the pathology. Interestingly, the transcription of metabotropic 
glutamate receptors as well as some of the ionotropic glutamate receptors seem to change concurrently.
 
The relationship between excessive glutamatergic stimulation and neurodegeneration has been 
demonstrated in several neurological systems [283-285], and the term 'excitotoxicity' was coined to describe 
it [284]. Glutamate is the major excitatory neurotransmitter in the mammalian CNS, but prolonged excess 
glutamatergic stimulation causes neuronal apoptosis [286, 287]. This phenomenon has been shown to play 
a role in neurodegeneration not only in AD [288, 289] but also in models of Parkinson's disease [290], brain 
and spinal cord injury [291], multiple sclerosis [285] and amyotrophic lateral sclerosis [292]. The NMDA 
receptor blocker Memantine, one of the most commonly prescribed drugs to treat Alzheimer's disease is 
based on the attenuation of glutamatergic signaling [293, 294].
Thus increased glutamate stimulation has been shown to be linked especially with NMDA-type glutamate 
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receptors. In our paradigm however, we see a concommitant upregulation of all types of glutamate receptors 
with the changes in metabotropic glutamate receptors (mGluRs) being most prominent.
4.2 RNA in the study of Alzheimer's disease
4.2.1 Gene and microRNA expression in mouse models of brain amyloidosis
Since the molecular mechanisms in human AD can only be studied post-mortem, a number of studies have 
been constructed in mouse models that overexpress amyloid-beta and in cell culture after addition of amyloid-
beta. We used one of these models, the APP-PS1 double transgenic model of amyloid overexpression to 
study the mRNA and microRNA expression changes. The results in Fig 3.2.1 show a small significant 
change in microRNAs during early disease, and fewer changes at an older age group. A study similar to 
ours, performed in the APP23 mouse line, a single transgenic line that overexpresses mutant human APP 
also showed evidence of microRNA dysregulation [295]. In these mice, which develop amyloid plaques 
later than the double transgenic mice we used, hippocampal expression of 9 microRNAs was studied by 
qPCR at various ages. the authors reported a downregulation of  nearly all tested microRNAs (mmu-miR-9, 
-181c, -409-3p, -361, 148b, -21,-let-7i, and -30c) at 7-8 months of age, and a return to a relatively normal 
microRNA profile at later ages. 
Interestingly, 2 of the 6 microRNAs that we found to be downregulated in the APP-PS1 mice (mmu-miR-9 and 
mmu-miR-409c)  overlap with the list previously generated [295] in the single transgenic mice. Further the 
timing of microRNA dysregulation with respect to plaque forming age is also similar. The peak in microRNA 
expression abnormalities appears to occur relatively early in the pathogenesis, just before the appearance 
of large, distinct plaques and behavioral manifestations. A previous microarray study in the cerebral cortex 
of another double transgenic APP-expressing strain also showed evidence of disturbance in microRNA 
levels, with 37 microRNAs being differentially expressed, including downregulation of mmu-miR-29a and 
-106b and upregulation of miR-34a [296]. This study also showed a peak in microRNA deregulation during 
the peak plaque-forming age, when soluble A-beta levels are highest, before large and extensive plaques 
developed.
Aside from the two microRNAs mentioned above, the list of differentially expressed microRNAs in the 
APP-PS1 double transgenic mice differs from the list obtained by the previous study. There is more than 
one possible reason for this discrepancy between the results. The mouse strain we use develops plaques 
and cognitive symptoms earlier than the APP23 strain, and it is possible that the ages used (4 months 
and 8 months) are too late to capture the early disruption in miRNA levels. The methodology used also 
differs between the 2 studies; our study is a genome-wide profiling, while Schonrock et al. use a targeted 
approach. The relatively stringent correction for multiple testing used in our NGS study could have caused 
a lowering of sensitivity to small changes in microRNA expression. 
Aside from these studies, the other investigations into microRNA disruption caused by A-beta have been 
conducted in vitro. The microRNAs hsa-miR-106a, -520c [297], -101 [298, 299], members of the miR-20a 
family [300], and miR-655, -323-3p, -644, -153 [301] all reportedly target APP through binding sites on 
its 3' UTR. MiR-124, the most abundantly expressed microRNA in human neuronal cells, has also been 
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suggested to play a role in the regulation alternative splicing of APP mRNA. MicroRNAs may also indirectly 
regulate levels of amyloid by targeting the beta-secretase BACE. MicroRNAs hsa-miR-29a, -29b-1, and -9 
show an inverse correlation with BACE protein levels in AD patients, and in a cell culture overexpressing 
mutated APP, they were able to suppress the production of A-beta peptides [302]. Evidence from mouse 
models, however, disputes the link between miR29a/b and BACE [303]. APP and amyloid have also been 
shown to cause downstream effects on microRNA networks. Adding fibrillar A-beta42 to primary neurons 
was shown to cause alterations in a large number of microRNAs in both directions [295].  
 
Although A-beta has a strong link with AD, human AD is associated with several other pathomechanisms, 
which are not recapitulated by overexpression of APP or treatment with A-Beta [303]. Since the development 
of a mouse model that replicates the tau pathology and all the other characteristics of AD in addition to 
the A-beta has proved difficult, microRNA studies on the AD-afflicted brain have thus far have largely 
been limited to postmortem analyses in humans.  A qPCR array in different brain regions of AD patients 
at various Braak stages showed that the expression of several microRNAs such as hsa-miR-200c, -212, 
-26a, -27a, -30c, -30e5p, -34a, -381, -422a, -423, -9, -92, (p value < 0.05, no correction for multiple testing) 
[304] changed with advancing AD. Subsequently, microarray analysis of the AD parietal cortex showed 
40 differentially expressed microRNAs, the top 10 being miR-30184, -617, -101, -06383, -10912, -20546, 
-601, 29b, -181c and -23974  (multiple testing correction used, FDR < 0.05) [305]. The most recent study 
of microRNA changes in the AD brain used an nCounter (Nanostring technologies) method to show the 
deregulation of 35 miRNAs in the hippocampus of patients with sporadic AD [306].
Other studies focusing on specific microRNAs have shown changes in expression of the miR-29a/b family 
[302, 307], miR-107 [308, 309], miR-9 and miR-128 [310]. Thus a large number of microRNAs have been 
reported as differentially expressed, but the overlap between these studies is relatively small (Fig 4.2.1). 
Within the set of overlapping miRNAs are hsa-miR-132, hsa-miR 425, hsa-miR-200, hsa-miR-27, hsa-
miR-9, hsa-miR-29a/b and  miR-107, which have all been reported in more than one study as being altered 
in AD [311]. Interestingly, there is some disagreement between studies over the direction of dysregulation. 
While Lukiw et al. [310] report hsa-miR-9 and hsa-miR-128 to be upregulated in the hippocampus of patients 
with AD, these microRNAs have been reported as downregulated in the AD hippocampus in other studies 
[304, 306] 
A direct comparison of all the studies is somewhat difficult, because they have been conducted in different 
brain regions.  Fig 4.2.1 shows an overview of the overlap between various human studies on miRNA 
changes in the AD hippocampus. It can also be seen that there is little overlap between the microRNA 
changes in the human AD hippocampus and those in the hippocampus of transgenic amyloid mouse 
models.
 
Thus using the currently available methods of investigation, no consensus has emerged about the role that 
microRNAs play in disease, and evidence from living patients or patients in early stages of AD is lacking. 
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Human AD hippocampus studies
Cogswell et al. 2008 (11up, 7 down)
Lau, de Strooper et al. et al. 2013  (11up, 7 down)
APP mouse hippocampus studies
APP-PS1- Section 3.2.1 (6 up 10 down)
Schon rock et al. 2013, (1up, 8 down)
Schon rock APP-PS1
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 OVERLAP BETWEEN HUMAN AND MOUSE STUDIES
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C
Figure 4.2.1 Comparison between previous human and mouse microRNA studies of AD 
A: Overlap between differentially expressed microRNAs in 2 major genome-wide human studies of the 
human AD hippocampus, B:  Overlap between differentially expressed microRNAs in the hippocampus of 
the APP-PS1 mouse model (Section 3.2.1) and the APP mouse model(Schonrock et al. 2010) C and D: 
Overlap between differentially expressed microRNAs in mouse and human studies.
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4.2.2 Feasibility of RNA isolation from CSF
As discussed in the section above, the methods for studying RNA profiles in the early stages of Alzheimer's 
disease are limited. Thus the possibility of studying brain-derived RNA-containing vesicles would provide 
a new insight into the pathomechanisms at all stages of disease. However, until recently it was not clear 
that RNA exists in a stable form outside cells. One of the earliest descriptions of RNA, published in the 
1960s describes it as an "unstable intermediate for carrying information from genes to ribosomes"[312]. 
Since then, and after the currently used standard method for RNA isolation, by guanidium thiocyanate–
phenol–chloroform (TRIzol or TRI-reagent) [313, 314], was established for extraction of RNA from plant 
and animal tissues, the process of RNA isolation is still generally known to require great care to protect 
RNA from degradation by ubiquitously occurring RNases. It has been generally held that cellular RNA 
is protected from degradation by special intracellular conditions and while being isolated from the cell, it 
needs additional protection from RNases. This emphasis on the instability of RNA was perhaps responsible 
for the long-held assumption that non-degraded RNA can only be isolated from intact cells and tissue. 
This assumption has recently been challenged. From Fig 3.2.2 as well as recently published literature (See 
section 1.2.4) it is now clear that RNA can be successfully isolated from cell-free biological fluids such as 
cell culture media, CSF and plasma. There are several mechanisms such as encapsulation in vesicles 
or lipoprotein complexes now known to protect RNA, especially microRNA, from degradation when it is 
circulating in extracellular fluid. While microRNAs in plasma have been shown to be especially resistant to 
endogenous RNAse degradation [315], from our observation and those of others [316, 317], it is evident 
that mRNAs can also be extracted from body fluids with a high degree of reproducibility.
The results we obtained regarding the RNA contents of the vesicular fractions of CSF were since confirmed 
in extracellular fluid from cell culture. A study comparing the RNA content of apoptotic bodies, microvesicles 
and exosomal vesicles isolated from 3 different cultured cell types established that the 3 kinds of vesicles 
have distinct RNA profiles. Apoptotic bodies have a high content of ribosomal RNA and their RNA profile 
resembles the cellular RNA profile, microvesicles contain little or no RNA, and exosomes are enriched in 
small RNA [318]. Though the highest number of microRNAs in our study are seen in the exosomes (around 
150), this number is far lower than the number of microRNAs that can be detected from human brain 
cells. However, evidence from neuronal cultures (Fig 3.2.4) suggests that exosomes carry a repertoire of 
microRNAs that is comparable to that in the cells. Thus the relatively low number of microRNAs isolated in 
exosomes points to the need for a more sensitive technique to preserve, isolate and detect RNA from CSF. 
It is possible that the exosome-free fraction of CSF contains RNA bound to proteins or lipoproteins, that 
are not efficiently extracted by the method we used. Another possibility is that a part of the RNA is suffers 
degradation during the exosome isolation procedure. Around the time that this thesis was written an NGS 
study of CSF microRNA detected 486 microRNAs in total, unfractionated CSF [319]. 
4.2.3 Choice of methods for RNA isolation from CSF 
However the isolation of RNA from extracellular fluids is complicated by the availability and widespread use 
of a large number of different RNA isolation methods and proprietary commercial reagents. The differences 
between these methods are at the levels of lysis reagent (guanidium thiocyanate–phenol–chloroform, 
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detergents or a combination) and RNA precipitation (simple precipitation or elution after precipitation on 
a column). In the case of exosomal RNA and other circulating RNA, the choice of RNA isolation method 
appears to be of particular importance. A study comparing various RNA isolation methods used on exosomes 
from cultured cells showed that not only the quantity but also the size profile of the isolated RNA differed 
based on the methods used [320]. Other studies comparing methods for the isolation of circulating RNA 
reported that the methods that lead to larger total RNA yields are not necessarily those that yield the best 
detection of microRNAS [319], indicating that some of these methods may be selective for certain RNA 
populations. However, that the results of these comparative studies cannot be generalized, and sometimes 
conflict with one another. While one study showed that the Exiqon miRCURY Biofluids Kit as the best-
performing method to isolate RNA from circulating body fluids [321], a simultaneous one that used this kit 
[322] reported the inability to isolate and detect microRNAs from CSF that were detected by us using the 
TRI-Reagent.
All in all, it appears that reproducibility of the results depends quite heavily on the choice of RNA isolation 
methods. For this reason, we chose the TRI-Reagent method over commercial RNA isolation kits with 
undisclosed proprietary reagents, and used this method consistently for all RNA isolation from fluids, cells 
and tissue.
4.2.4 RNA species in CSF exosomes
Though exosomes are derived from cells, their RNA profile is distinct from the cellular profile. Based on our 
results and those from other published studies, exosomes appear to be enriched in RNA below 200 nt in 
size and are rich in non-coding RNA.
4.2.4.1 Small RNA enrichment in CSF exosomes
The size profile of the RNA we isolated from CSF exosomes matches that described in the literature for 
RNA isolated from various cell types and biological fluids [323-326]. The repeated finding of a large peak 
in the small RNA region, and the virtual absence of RNA species above 200nt in length raises several 
questions, as does the absence of the ribosomal RNA subunits that dominate the cellular RNA profile. 
One possibility is that the observed profile represents degraded cellular RNA, with the larger RNAs being 
degraded and the smaller ones being more resistant to degradation. However, the consistent well-defined 
nature of the small RNA peak suggests otherwise. The other possibility is that the cells apply a machinery 
that targets specific small RNAs to exosomes. 
A closer look at the size distribution of exosomal RNA reveals that this peak is not in the mature microRNA 
region  (22˗26 nt), but lies between 100-150 nt in exosomes from CSF, plasma, and cell culture. While 
exosomes clearly contain numerous microRNAS and mRNAs (Fig 3.2.3.2 and 3.2.3.3), the other RNA 
contents of the exosomes remain to be explored. Next-generation sequencing (NGS), a high throughput 
method which can be used to reconstruct RNA sequences before mapping them to the genome could 
thus prove highly valuable for this purpose. In this context, one particular advantage of NGS over array-
based technology is that we are not limited to the known and well-annotated species such as mRNAs and 
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microRNAs but can potentially study the lesser known non-coding RNAs.
 
The first study to sequence the contents of exosomes was performed in cultured immune dendritic cells 
[327]. This study presumed that the peak consisted of tRNAs and excluded it from their sequencing protocol, 
only sequencing RNA species below 70nt in length. However, tRNAs are commonly known to be 70-95nt 
in length, and would not fully explain the observed RNA profile. A similar study in exosomes from prion-
infected neuronal cells, also selectively sequenced the RNAs below 40nt in length, labeling the higher peak 
as tRNA [328]. 
A study of RNA in exosomes derived from saliva [329] and one of microparticles circulating in plasma 
sequenced the entire 20‒200nt region, but mapped and reported only the microRNA contents [330]. 
Between the publication of the results of the first sequencing of exosomal contents in 2012 and the writing 
of this thesis, there have also been several qPCR- and array-based investigations published into RNA 
contents of the exosome, focusing mostly on the microRNAs and mRNAs [329]. It has been shown in at 
least one cell type that microRNAs are relatively depleted in exosomes compared to cells [328], and the 
bioanalyzer profile of exosomal RNA suggests the abundant presence of other RNA species below 200nt. 
Some possibilities that could lie in this region are 5S ribosomal RNA, tRNA, pri-microRNAs and a host 
of other non-coding RNAs about which little is known. Several non-coding RNAs below 75 nt in length 
have been found such as Y RNAs, vault RNAs, specific t-RNA repeat regions, and other repeat regions 
[327]. There is also evidence that microvesicles secreted from glioblastoma cells contain retrotransposon 
sequences and other repetitive elements, with some of them such as Alu-1 and L1 being highly enriched in 
the vesicles over the cells [331]. It remains to be seen if exosomes from non-malignant cells also contain 
retrotransposon elements, but the possibility raises interesting questions about the role that extracellular 
vesicles play in intercellular information transfer. Thus there is still much to be studied about the exosomal 
RNA content beyond the microRNA and protein-coding transcripts.
However, the mapping of these non-coding RNAs to the genome after sequencing poses a significant 
challenge, with few established methods to perform this task. Little is known about the physiological 
function of many of these RNA types and the annotation databases for other non-coding RNA microRNA 
are relatively new and still not as comprehensive as those for mRNA or miRNA. The nature of the repeat 
sequences also makes their alignment to the genome technically more difficult.
4.2.4.2 MicroRNA contents of CSF exosomes
Our results represent the first sequencing study of exosomes from cerebrospinal fluid. RNA and microRNA 
has previously been identified in the CSF by qPCR [304, 322], microarray [332] in smaller scale studies, 
where all fractions of CSF RNA (cell debris-, vesicle- and lipoprotein-associated RNA) were pooled together. 
Around the time that the work described in this thesis was completed, the first NGS profiling of plasma and 
cerebrospinal fluid was published [319]. The number of microRNAs we detected in CSF exosomes was 
comparable with the number detected by this profiling study of whole CSF. However, the microRNA profile 
we detected in exosomes was not very similar to the microRNA profile detected in whole CSF. For example, 
the most abundant microRNA in CSF exosomes was hsa-miR-204, while the top miRNA in whole CSF was 
hsa-miR-486 [319]. Interestingly, hsa-miR-486 is the most abundant microRNA in plasma exosomes. These 
results suggest that the CSF exosomes contain a distinct set of microRNAs.
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The finding that exosomes are slightly depleted in microRNA as compared to their cells of origin replicates 
published observations in immune dendritic cells [327]. Similarly, the selective enrichment and depletion 
of certain microRNAs in exosomes has also been confirmed recently in a study of exosomes from a 
neuronal cell line [328]. While it is easy to imagine that certain cellular microRNAs may not be exported into 
exosomes, the presence of microRNAs in exosomes that are not detectable in cells is hard to explain. This 
finding is thus most likely attributable to the detection limits of the method used.
4.2.4.3 Other non-coding RNA in CSF exosomes
One of the better known long noncoding RNA highly expressed in the CSF exosomes is Neat1 or Nuclear-
Enriched abundant transcript1. Neat1 RNA is essential for the formation of specialized subcellular structures 
called paraspeckles [333]. Paraspeckles are dynamic transcription-dependent granules that contain 
ribonucleoprotein and RNA [334]. Neat1 is thought to play a role in preventing inappropriate translation 
and regulating nuclear export of RNA containing inverted repeated Alu elements. The presence of Neat1 
in exosomes, which have no known connection with the nucleus is thus interesting. Neat1 and other 
paraspeckle-related genes were also found to be strikingly upregulated in the hippocampus of aged mice 
[335] (unpublished).  
Among the smaller non-coding RNAs, in the 40-200 nt regions, the most abundant transcripts belong to the 
Y RNA family. Y RNAs, which are RNA polymerase III transcripts have been shown to be highly enriched 
in extracellular vesicles from cultured cells [327]. They bind to the Ro ribonucleoprotein and have been 
studied mostly in the context of systemic lupus erythematosus.
In one of the samples (Sample 2), the most abundant transcripts are from the U RNA family of small nuclear 
RNAs. The U RNAs, a family of RNAs associated with the spliceosomal complex,  and bind closely to small 
nuclear ribonucleoproteins. Interestingly, the U1 ribonucleoproteins have been recently shown to play a 
role in AD, perhaps through dysregulation of RNA splicing [336]. Thus the most abundant known non-
coding RNAs from both the smaller and larger fractions of CSF exosomal RNA are associated with nuclear 
complexes, raising the question of how they are trafficked from the nucleus into exosomes.
4.2.5 Exosomal RNA as an indicator of intracellular changes
The overall finding that the exosomal RNA profile does not replicate that of the cell that it originates from 
is interesting because it demonstrates that the RNA secretion into exosomes is not a passive process, 
but rather a non-random selective one. Thus the excretion of RNA by the cell into exosomes might serve 
a functional purpose. However, it is not yet clear whether this purpose is the excretion of unwanted RNA 
intended for degradation or intercellular communication by RNA transport or both.
The results in Fig 3.2.4 indicate that the profile of microRNAs exported in exosomes changes during cellular 
response to insults. The distinct unsupervised separation between exosomes from untreated cells and 
exosome from A-beta-treated cells suggests that at least under carefully controlled in vitro conditions, 
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exosomal RNA can be used to indicate the status of the neurons they originate from. The situation in a 
biological fluid like CSF or plasma is likely to be complicated by the fact that exosomes isolated from these 
fluid are likely to originate from a multitude of sources, with no currently available means to determine the 
individual contribution of each cell type to the exosome population.
The treatment of primary neurons with A-beta is a method notorious for its high variability from culture to 
culture and small differences in A-beta preparation methods are known to affect the results unpredictably. 
Further, the number of replicates used here is admittedly too small to allow extrapolation about the general 
effects of A-beta on neuronal or exosomal microRNA profiles. Yet, the list of differentially expressed 
neuronal microRNAs obtained after A-beta treatment under the conditions we used shows some overlap 
with a previous study of A-beta induced deregulation of microRNAs in hippocampal neuron cultures.
The opposite-direction shifts in the proportion of small non-coding RNA and long RNA in cells and exosomes, 
is interesting and appears to suggest that cells under stress by A-beta toxicity excrete more mRNA and long 
noncoding RNA into exosomes. Confirming these shifts and further investigating the selective secretion of 
certain RNA classes into exosomes would require a time course profiling of RNA in cells and exosomes 
after A-beta perturbation. While these experiments could potentially provide further insights into exosome-
cell relationships,  they are not within the scope of the currently described work.
4.2.6 Potential for use of CSF RNA as a biomarker for AD
The random forest machine learning algorithm we used not only gives an estimate of prediction accuracy 
but also ranks variables based on their relative contribution to differentiating between groups. Based on 
the measure of variable importance used by the algorithm, hsa-miR-34c appears to be the microRNA with 
the highest power in differentiating between AD patients and controls. At the level of the individual miRNA, 
miR-34c is also significantly higher in AD patients than controls. When the effect of age on the levels of this 
microRNA was examined, miR-34c showed a trend towards increase with age, but no significant difference 
between young and old groups. These results fit well with the published literature. MiR-34c has been shown 
before to be increased in the hippocampus of patients with AD [226]. A recent examination of microRNA 
levels in the hippocampus of patients with AD, showed that this increase was specific to the early stages 
of AD [322]. Further evidence for the involvement of 34c in AD and age-associated memory impairment 
comes from a mouse study showing that inhibition of 34c can rescue amyloid-induced as well as aging-
induced learning deficits [226]. 
Since age is the biggest risk factor for AD, the age-related changes in miRNA expression are hard to 
separate completely from those associated with disease. In view of the published literature with regard to 
this particular microRNA, these results can be interpreted as meaning that AD is associated with a large 
increase in miR-34c on a background of a smaller increase with aging. An alternative possibility is that 
34c marks accelerated aging in the brain, and signifies an enhanced risk for AD. In either case, the results 
validate the potential of CSF exosomal microRNA as a method to study molecular pathophysiology in the 
living AD brain. 
Among the other microRNAs that seemed to differentiate between groups included miR-146b, which has 
been shown before to be downregulated in the human AD hippocampus [304] and miR-181a-3p. Thus, 
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although more than one of these microRNAs is significantly different between groups, none of them is 
individually able to accurately predict disease status. Interestingly, some of the top predictive microRNAs 
were not significantly differentially expressed between groups, and the most significantly differentially 
expressed microRNA (miR-598) was not among the most predictive microRNAs. It is conceivable that a 
combination of up- and down-regulation patterns of a set of microRNAs together indicate an underlying 
pathological process. In such a situation, a learning algorithm is clearly more suited to the task of developing 
a 'disease signature' than manually selecting microRNAs based on differential expression between groups.
Conclusions

4.3.1 RNA in age-associated memory impairment
The work described in section 2.1 aimed to identify the molecular mechanisms that distinguish healthy 
cognitive aging from age-associated memory impairment. Based on these experiments we concluded that
•	 As in humans, aging is associated with a decrease in performance on learning and memory tasks 
in mice. This decline does not occur at a uniform rate, but varies greatly from individual to individual. Thus 
there is high intra-group variability in age-associated memory decline.
•	 The water maze spatial learning task provides a useful model to study this heterogeneity in aging 
wild-type mice and can be used to distinguish good learners from poor learners within a group.
•	 The expression levels of a large number of genes correlate with water maze performance in aging 
mice. Analyzing these data by the GSEA technique defines sets of genes in the pathways associated with 
ribosomes and translation to be correlated with good performance. Conversely, the high expression of 
genes in the glutamate signaling pathway were found to be associated with poor performance.
•	 Comparing the levels of gene expression in the 3 best-performing individuals with the 3 worst-
performing individuals confirmed that genes in the pathway associated with translation initiation are 
expressed at higher-than-average levels in the aging mice with good memory skills. Similarly, the 3 worst-
performing mice expressed glutamate receptors and other components of the glutamate signaling pathway 
at higher-than average levels.
4.3.2 CSF exosomal RNA in the study of AD
The experiments described in section 2.2 were designed to establish and test a novel method of studying 
the molecular mechanisms in the brain of live patients with Alzheimer's disease. Extracellular vesicles 
from cerebrospinal fluid were isolated and used as sources of RNA to provide an insight into the cells they 
originated from. 
•	 This work shows that CSF contains stable RNA species that can be reproducibly isolated and 
quantified, and that when using the methods described, the majority of RNA detected in CSF is in exosomal 
vesicles or is associated with them. 
•	 Using next-generation sequencing to study the RNA contents of CSF exosomes revealed that a 
small fraction of the RNA was microRNA, another small fraction consisted of mRNA and a large proportion 
of the RNA was other non-coding RNA.
•	 The list of RNA transcripts in exosomes overlaps the list of transcripts in the neurons from which it 
originates, with certain RNA and microRNA species being enriched in the exosome. Perturbation of the cell 
by amyloid-beta treatment is reflected clearly by a change in the exosomal RNA content, but the exosomal 
RNA profile is distinct from the cellular RNA profile.
•	 Increase in CSF exosomal levels of microRNA 34c were detected by an unbiased screen of 
exosomal RNA to be associated with Alzheimer's disease. Interestingly, this microRNA has been linked to 
AD by both animal and human studies before. This finding shows that studying CSF could be a method to 
detect more coding and non-coding RNAs involved in AD.
•	 CSF exosomal RNA can be used to differentiate patients with Alzheimer's disease from control 
subjects with a reasonable degree of accuracy, given the relatively small number of samples used in this 
study. Studying the CSF RNA from a larger number of patients would help provide an insight into its potential 
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Appendix 1: Notes on Gene set enrichment analysis
Gene set enrichment analysis (GSEA), is a tool that was developed to help study the biological 
significance to the large amounts of gene expression data generated by genone-wide studies such as 
microarrays [1].  This approach relies on prior biological knowledge to search for sets of genes whose 
expression is increased or decreased in the given gene list. Some examples of the 'sets' of genes used 
in GSEA are functionally related genes within Gene Ontology (GO) terms, genes in a pathway such as 
a KEGG pathway, genes within a defined chromosomal proximity, and genes with common transcription 
factor or miRNA binding sites. The main steps involved in GSEA are as follows : A list of genes weighted 
or ranked by expression change(fold change or P value) is generated based on user input. An enrichment 
score is calculated  for the gene sets of interest and statistical significance is estimated and adjusted for 
multiple testing. Thus the analysis is focused on assigning significance values to a related group of genes 
rather than to individual transcripts.
One advantage of GSEA over a conventional differential expression analysis with a p-value cutoff is that 
GSEA has the ability to identify subtle or low-volume changes that occur across a set of related genes. 
This is particularly useful in identifying key regulatory networks in a situation where several genes in 
a pathway or functional category show small changes, but only a handful of them pass the arbitratry 
significance threshold.
In the work described in this thesis, as well as in other published studies, the criteria used to select 
the input list of genes are not very stringent and the resulting list is often large. This list may include all 
genes which change significantly with an unadjusted p value, or even the entire list of expressed genes, 
weighted by fold change or P value. The correction for multiple testing is then performed at the level of 
the gene set, rather than individual genes. The standard implementation of GSEA, available from the 
Broad Institute was used in this work, but many other methods to implement GSEA and to use custom 
gene sets for analysis also exist. Since its forst description in 2005 [1], GSEA has been used in a large 
number of studies and is a widely accepted method of analyzing genome-wide expression data.
1. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, 
Pomeroy SL, Golub TR, Lander ES et al: Gene set enrichment analysis: a knowledge-based 
approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of 
Sciences of the United States of America 2005, 102(43):15545-15550.

Appendix 2:  Notes on the Random Forest machine learning algorithm 
and the Gini Index
The Random Forest algorithm is a machine learning method for classification of data (1). It works by 
classifying the samples using a large number of random decision trees, with one or more features used 
to perform the split at each node. This algorithm was chosen for the task because of its high accuracy 
and low likelihood of ‘overfitting’. Further, this method provides an inbuilt means, through bootstrapping 
to conduct internal cross-validation and estimate error rates (out-of-bag error rates) and to calculate the 
relative importance of the variables used.  
Note on interpretation of Decrease in Gini Index
The ‘Decrease in Gini Index’ is the method of choice for rapid estimation of the relative importance of 
variables or their contribution to effect being studied in a random forest algorithm (2). The Gini Index is 
a widely used statistical measure of inequality (3). In each tree of the constructed forest, when the given 
variable is used to split samples, the Gini Index or inequality in the resulting groups is measured. An 
important or useful variable would lead to an accurate splitting and thus the new group formed would be 
more homogenous. This would lead to a decrease in Gini index, which is measured by the algorithm and 
averaged over all the trees.
1. Breiman, Leo (2001). “Random Forests”. Machine Learning 45 (1): 5–32. 1. 
2. A. Liaw and M. Wiener (2002). Classification and Regression by randomForest. R News 2(3), 18--22
3. Gini, C. (1912). “Italian: Variabilità e mutabilità” ‘Variability and Mutability’, C. Cuppini, Bologna, 156 
pages. Reprinted in Memorie di metodologica statistica (Ed. Pizetti E, Salvemini, T). Rome: Libreria Eredi 
Virgilio Veschi (1955) 
